

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [editorial.bmjopen@bmj.com](mailto:editorial.bmjopen@bmj.com)

# BMJ Open

## Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: A meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016053
Article Type:	Research
Date Submitted by the Author:	06-Feb-2017
Complete List of Authors:	Zhao, Tong; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Chen, Baomin; First Affiliated Hospital, Chinese Medical University, liver and gall surgical Zhou, Yingying; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Wang, Xinyi; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Zhang, Yuanyuan; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Wang, Haoyu; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Shan, Zhongyan; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Nutrition and metabolism, Cardiovascular medicine
Keywords:	subclinical hypothyroidism, carotid intima-media thickness, thyroxin, cardiovascular risk

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Effect of levothyroxine on the progression of carotid intima-media**  
5  
6  
7 **thickness in subclinical hypothyroidism patients: A meta-analysis**  
8  
9

10  
11 Zhao Tong, Chen Baomin, Zhou Yingying, Wang xinyi, Zhang yuanyuan, Wang haoyu, Shan

12  
13  
14  
15  
16 Zhongyan

17  
18  
19  
20 *Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning*

21  
22  
23 *Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China*

24  
25  
26 *Medical University, No.155 Nanjing North Street, Shenyang 110001, China*  
27

28  
29  
30 the email address of the corresponding author

31  
32  
33 *Zhao, Tong* [cmu\\_zhaotong@163.com](mailto:cmu_zhaotong@163.com)

34  
35  
36  
37 *Chen, Baomin* [cbm19910330@163.com](mailto:cbm19910330@163.com)

38  
39  
40  
41 *Zhou, Yingying* [18937856536@163.com](mailto:18937856536@163.com)

42  
43  
44  
45 *Wang, Xinyi* [wangxinyi4125@163.com](mailto:wangxinyi4125@163.com)

46  
47  
48 *Zhang, Yuanyuan* [yuan-anpo@163.com](mailto:yuan-anpo@163.com)

49  
50  
51 *Wang, Haoyu* [why\\_endocrinology@foxmail.com](mailto:why_endocrinology@foxmail.com)

52  
53  
54  
55 *Shan, Zhongyan (Corresponding Author)* [shanzhongyan@medmail.com.cn](mailto:shanzhongyan@medmail.com.cn)

56  
57 **Abstract**

58  
59 1 / 39  
60

1  
2  
3  
4 **Background and aims:** Subclinical hypothyroidism (SCH) has been associated with  
5  
6  
7 increased carotid intima-media thickness (C-IMT) in recent studies, but the effects of  
8  
9  
10 levothyroxine (L-T4) on C-IMT in SCH patients are still controversial. The aim of the current  
11  
12  
13 study was to evaluate the effect of L-T4 therapy on endothelial function as determined by  
14  
15  
16  
17 C-IMT in patients with SCH.  
18  
19

20  
21 **Methods:** Prior to July 2016, we searched the PUBMED, EMBASE, COCHRANE  
22  
23  
24 LIBRARY and GOOGLE SCHOLAR databases we selected published randomized  
25  
26  
27 controlled trials (RCTs) and self-controlled trials.  
28  
29

30  
31 **Results:** Three RCTs with 117 patients were considered suitable for the meta-analysis. The  
32  
33  
34 results of the meta-analysis indicated that L-T4 significantly decreased the development of  
35  
36  
37 C-IMT [weighted mean difference (WMD), -0.05 mm, 95% CI -0.08, -0.01; p = 0.025]. We  
38  
39  
40 also analysed 9 studies (self-controlled trials) with 247 patients and extracted the IMT of  
41  
42  
43 SCH patients before and after L-T4 treatment. After L-T4 therapy, the pooled estimate of the  
44  
45  
46 WMD of decreased C-IMT was -0.03 mm (95% CI -0.05, -0.01; p = 0.001). Subgroup  
47  
48  
49 analysis showed that L-T4 therapy was associated with a decrease in C-IMT among patients  
50  
51  
52 of mixed gender (WMD, -0.03 mm, 95% CI -0.05, -0.01; p = 0.002). Longer treatment (>6  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 months) also resulted in a significant decrease in C-IMT (WMD, -0.05 mm, 95% CI -0.08,  
5  
6  
7 -0.02; p=0.001).

8  
9  
10 **Conclusion:** This meta-analysis indicates that L-T4 treatment of SCH patients can reduce  
11  
12  
13  
14 C-IMT, possibly as a result of the reduction of TC, TG, LDL-C, SBP, DBP, LP(a), and FMD.  
15  
16  
17 Decreased C-IMT was observed in SCH patients after long-term (>6 months) L-T4 treatment.  
18  
19  
20  
21 RCTs with large samples are needed to verify these observations.  
22

### 23 24 *Strengths and limitations of this study:*

#### 25 26 *Strengths*

27  
28 A strong quality evidence on the effect of L-T4 therapy in SCH patients is  
29 preformed  
30  
31 Long-term treatment significantly improves C-IMT compared with short-term  
32 treatment.  
33  
34 We performed meta-analysis of RCTs.  
35  
36 We also performed meta-analysis of self-controlled trials.  
37  
38 We analysis other metabolic parameters  
39

#### 40 41 *Limitations*

42  
43 The number of including studies was small, and the overall population of these trials  
44  
45  
46 was not large. Additionally, we did not perform subgroup analysis according to the  
47  
48  
49 level of TSH (the cutoff value is 10 mU/ml to distinguish mild SCH and severe SCH)  
50  
51  
52  
53 because the original studies did not perform analyses according to the level of TSH.  
54  
55

1  
2  
3  
4 Finally, we did not perform subgroup analysis by mean age (>65 or <65 years)

5  
6  
7 because all participants' mean age was below 65 years.  
8  
9

10  
11  
12  
13  
14  
15 **Keywords:** subclinical hypothyroidism; carotid intima-media thickness; thyroxin;

16  
17  
18 cardiovascular risk  
19

## 20 21 22 23 **Introduction**

24  
25  
26 Subclinical hypothyroidism (SCH) is characterized by a normal range of free thyroxin  
27  
28 concentrations together with increased serum thyroxin (TSH) levels. Recently, SCH was  
29  
30 found in 5% to 10% of the general population and 6% to 10% of women (approximately 15%  
31  
32 was found in women more than 60 years old), while the incidence in males is 2.4 to 3% [1].  
33  
34  
35  
36  
37  
38

39  
40 Although SCH is frequently asymptomatic, approximately 30% of patients have symptoms  
41  
42 indicative of thyroid hormone deficiency [2, 3]. However, the clinical significance and  
43  
44 therapeutic strategies of SCH are controversial .  
45  
46  
47  
48

49  
50 Overt hypothyroidism is a well-known risk factor for cardiovascular disease and  
51  
52 atherosclerosis [4]. A large-scale population-based study also concluded that SCH was an  
53  
54 independent risk factor for atherosclerosis among elderly women [5]. We have proposed  
55  
56  
57  
58

1  
2  
3  
4 several mechanisms for this association, including dyslipidaemia [6]; high blood pressure [7];  
5  
6  
7 higher prevalence of metabolic syndrome [8]; endothelial dysfunction [9]; insulin resistance  
8  
9  
10  
11 [10]; increased carotid intima-media thickness (C-IMT) [11]; hypercoagulability [12] and  
12  
13  
14 oxidative stress [13]. C-IMT is a generally acknowledged measure of subclinical  
15  
16  
17 atherosclerotic alterations. It is increasingly used to evaluate vascular function in clinical  
18  
19  
20  
21 analyses assessing the efficacy of interventions that reduce atherosclerosis and related  
22  
23  
24 diseases [14]. This parameter is listed in the European guidelines for prophylaxis of  
25  
26  
27 cardiovascular disease, and 0.9 mm is the threshold value for C-IMT. Progression of  
28  
29  
30 atherosclerosis is indicated when the value of C-IMT is over the threshold. Several studies  
31  
32  
33  
34 have demonstrated the relationship of C-IMT to primary cardiovascular risk factors [15, 16].  
35  
36  
37  
38 For a 0.1 mm difference in C-IMT, the prospective risk of myocardial infarction increased  
39  
40  
41  
42 from 10% to 15%, and the stroke risk was increased from 13% to 18% [17].  
43  
44

45 A meta-analysis involving 8 studies with 3602 participants found a relationship between  
46  
47  
48 SCH and C-IMT, especially when TSH > 10.0 mIU/l [11]. L-T4 replacement should be used  
49  
50  
51  
52 to treat patients with clinical hypothyroidism; however, the treatment of SCH is complex.  
53  
54  
55  
56 Several placebo-controlled studies have shown the beneficial effects of L-T4 therapy on early  
57  
58

1  
2  
3  
4 atherosclerotic alterations and cardiovascular hazard in patients with SCH [16, 18]. Recently,  
5  
6  
7  
8 in a large-scale retrospective cohort study examining the efficacy of L-T4 replacement on  
9  
10  
11 cardiovascular mortality, myocardial infarction and all-cause death, no beneficial effects in  
12  
13  
14 patients with SCH were found, except for patients under 65 years old [19]. The endothelial  
15  
16  
17 function in SCH and the effect of L-T4 treatment in ameliorating endothelial dysfunction are  
18  
19  
20 still unclear. The purpose of the current study was to evaluate the effect of L-T4 therapy on  
21  
22  
23  
24  
25  
26  
27 endothelial function as evaluated by C-IMT in patients with SCH.

## 28 **Methods**

### 31 **Search strategy**

32  
33  
34  
35  
36  
37 Studies published in English were found in the EMBASE, PUBMED, GOOGLE SCHOLAR  
38  
39  
40 and COCHRANE LIBRARY electronic databanks prior to June 2016. We identified studies  
41  
42  
43 that measured IMT in patients with SCH before and after treatment with L-T4. Studies were  
44  
45  
46  
47 obtained using three series of key items as subject headings: 1) hypothyroidism, thyroid  
48  
49  
50 disease, subclinical hypothyroid, subclinical thyroid dysfunction and thyroid-stimulating  
51  
52  
53  
54 hormone; 2) intima media thickness, IMT, carotid wall thickness, C-IMT and carotid  
55  
56  
57 atherosclerosis; 3) levothyroxine, thyroxin, L-T4, replacement, therapy and treatment. For a  
58  
59  
60



1  
2  
3  
4 thorough review of the literature, we searched more studies by browsing the references of the  
5  
6  
7 identified reports and review articles.  
8  
9

### 10 11 12 **Criteria for study selection** 13

14  
15 Subjects with SCH have standard free thyroxin levels and increased TSH levels. There is  
16  
17  
18 still debate about the TSH reference interval; several reviews have proposed a TSH upper  
19  
20  
21 cutoff between 4.5 and 5.0 mIU/l [20, 21], but some experts suggest that the peak TSH  
22  
23  
24 should be decreased to 2.5-3.0 mIU/l. Because there are no consistent conclusions, no  
25  
26  
27  
28 specific TSH cutoff was used to define SCH, but all articles had a cutoff point from 3.6 to 5.5  
29  
30  
31 mIU/l. To be included, a study had to satisfy the following conditions: 1) reported SCH  
32  
33  
34 defined based on a thyroid function test (normal free T4 and increased TSH); 2) defined as a  
35  
36  
37 RCT, which compared C-IMT in SCH patients in a L-T4 treatment and control group, or a  
38  
39  
40 self-controlled trial, which compared C-IMT value of a patient with SCH before and after  
41  
42  
43  
44  
45  
46 L-T4 replacement.  
47  
48

### 49 **Study selection** 50

51  
52  
53 Two investigators independently screened both abstracts and titles of the studies, and the  
54  
55  
56  
57 studies were excluded when they did not conform to the inclusion criteria or they accorded  
58

1  
2  
3  
4 with the exclusion criteria. Two investigators independently extracted data from the papers. If  
5  
6  
7  
8 there was disagreement, a third reviewer was asked for advice. Discrepancies were solved by  
9  
10  
11 unanimous agreement.  
12  
13

### 14 15 **Data extraction**

16  
17  
18  
19 The following information is contained in the data extraction table: 1) author 2) year of  
20  
21  
22  
23 publication 3) region 4) sample size 5) sample gender 6) mean age of the cohort 7) definition  
24  
25  
26  
27 of SCH 8) duration of SCH 9) SCH detection method 10) mean L-T4 dosage 11) duration of  
28  
29  
30  
31 treatment 12) thyroid function after treatment 13) IMT assessment 14) IMT values (mean  
32  
33  
34 with SD) before and after treatment with the corresponding treatment method.  
35  
36

### 37 38 **Assessment of study quality**

39  
40  
41  
42 The quality of non-randomized studies was evaluated using the MINORS method [22], which  
43  
44  
45  
46 is based on the following items: a stated aim of the study, inclusion of consecutive patients,  
47  
48  
49  
50 prospective collection of data, endpoint appropriate to the study aim, unbiased evaluation of  
51  
52  
53  
54 endpoints, follow-up period appropriate to the major endpoint, and loss to follow-up not  
55  
56  
57  
58 exceeding 5%.  
59  
60

1  
2  
3  
4 Methodological quality of the included RCTs was assessed using the Cochrane  
5  
6  
7 Handbook for Systematic Review of Interventions by several domains: generation of random  
8  
9  
10  
11 sequence; allocation concealment; blinding; incomplete outcome data addressed; free of  
12  
13  
14 selective reporting; free of other bias.  
15  
16

### 17 **Statistical analysis**

18  
19  
20  
21 We represented the results as weighted mean differences (WMDs) with 95% confidence  
22  
23  
24 intervals (CIs) for continuous variables. For continuous outcomes, if all reports had uniform  
25  
26  
27 units of measurement (expressed as mm), we showed the WMD and 95% CIs as the results.  
28  
29  
30  
31 We evaluated statistical heterogeneity across the studies by Cochrane's Q test ( $p < 0.1$  was  
32  
33  
34 statistically significant) and the  $I^2$  test ( $I^2 > 50\%$ : high heterogeneity;  $I^2 = 25\%$ - $50\%$ :  
35  
36  
37 moderate heterogeneity;  $I^2 < 25\%$ : low heterogeneity) [23]. The pooled effect size was  
38  
39  
40  
41 assessed with a random-effect model when significant heterogeneity was present; in contrast,  
42  
43  
44 we also selected a fixed-effect model.  $p < 0.05$  was considered significant. We assessed  
45  
46  
47  
48 publication bias with Begg's correlation test and Egger's regression method [24]. Sensitivity  
49  
50  
51  
52 analysis was carried out for all papers in addition to the studies with boundary qualification.  
53  
54

55  
56 Pre-specified subgroup meta-analyses were performed to assess the between-study  
57  
58

1  
2  
3  
4 heterogeneity on the basis of the gender of participants (female or mix) and duration of  
5  
6  
7 treatment ( $>6$  months or  $\leq 6$  months). Among 9 including studies, 3 out of them are RCTs and  
8  
9  
10 the other of them are self-controlled trials. We performed Statistical analysis of three RCTs.  
11  
12  
13 SCH treatment group of three RCTs also have the information on C-IMT values between  
14  
15  
16 pre-treatment and after-treatment in SCH patients. We combined the SCH treatment group of  
17  
18  
19 RCTs with the other self-controlled trials to performed Statistical analysis for fully revealing  
20  
21  
22 the effect of L-T4 treatment in SCH patients. Statistical analyses were performed with  
23  
24  
25  
26  
27  
28 STATA 11 for Windows.  
29  
30  
31

## 32 **Results**

### 33 34 35 36 **Study selection**

37  
38  
39  
40 Three RCTs [16, 25, 26] (57 patients treated with L-T4 and 60 included in the control group)  
41  
42  
43 were selected for the meta-analysis, with a total of 117 patients. A total of 9 publications  
44  
45  
46  
47 [16, 25-32] with 247 SCH patients measured the C-IMT before and after L-T4. We selected  
48  
49  
50  
51 these studies among 107 potentially related articles (Fig. 1).  
52  
53  
54

### 55 56 **Baseline characteristics and study quality**

1  
2  
3  
4 The baseline characteristics of the included trials are shown in Table 1(A)(B). The duration  
5  
6  
7 of therapy with L-T4 ranged from 2 to 18 months, the patient count varied from 14 to 56  
8  
9  
10 subjects, and the year of the publication was from 2004 to 2016. Six trials included female  
11  
12  
13 and male patients, and the other three only examined female patients. Based on the type of  
14  
15  
16 original research, the methodological evaluation of study quality was different. We used  
17  
18  
19 MINORS to assess the quality of the self-controlled trials. In general, the included self-controlled  
20  
21  
22 trials were of moderate quality (Table1). The results of RCT quality are shown in Fig. 2.  
23  
24  
25  
26  
27

### 28 **Progression of C-IMT in the follow-up and subgroup analysis**

29  
30  
31 A total of 3 RCTs involving 117 patients were analysed. L-T4 treatment significantly  
32  
33  
34 decreased C-IMT progression in SCH patients. (WMD, -0.05 mm, 95% CI -0.08, -0.01; p =  
35  
36  
37 0.025). The heterogeneity was very low ( $I^2=22.2\%$ ) (Fig. 3)  
38  
39  
40  
41

42 The nine self-controlled experiments compared the value of C-IMT before replacement  
43  
44  
45 and after treatment. After L-T4 therapy, the thyroid function of all patients was normalized  
46  
47  
48 from SCH, and then, patient IMT was measured again. L-T4 therapy was linked to a mild but  
49  
50  
51 significant decrease in the development of C-IMT (WMD, -0.03 mm, 95% CI -0.05, -0.01;  
52  
53  
54  
55 p = 0.001). The heterogeneity was very low ( $I^2=21.8\%$ ) (Fig. 4)  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 Subgroup analyses stratified by gender revealed that L-T4 therapy caused a significant  
9  
10  
11 decrease in C-IMT among patients of mixed gender (WMD, -0.03 mm, 95% CI -0.05, -0.01;  
12  
13  
14 p = 0.002). The outcomes showed low heterogeneity (I<sup>2</sup>= 39.2%). After L-T4 treatment,  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

TABLE 1(A). Summary of the Characteristics of the Included Studies

Author/ Year	Sample Size	Region	Gender	Mean Age (year)	Definition of SCH	SCH Duration (month)	L-T4 Dosage (initial value)	Treatment Duration (month)	Thyroid function after treatment	CIMT(mm) (Before/After)	Quality Score
Monzani 2004	23	Italy	mix	37±11	TSH >3.6 mIU/L	at least 6 months	25 -75 ug/d	10.5 <sup>d</sup>	normal	0.76±0.14 0.67±0.13	12
Soo-Kyung 2009	28	Korea	mix	36.0±6.2	TSH >5.5 mIU/L	newly diagnosed	67µg/d <sup>b</sup>	18 <sup>b</sup>	normal	0.67±0.11 0.60±0.10	9
Monica 2011	14	Brazil	female	43.4±9.8	TSH >4.0 mIU/L	—	44.23±18.13mg/d <sup>d</sup>	12	normal	0.66±0.11 0.66±0.15	10
Levent 2010	38	Turkey	mix	49.8±10.0	TSH >5.0 mIU/L	at least 2 months	101±27.46µg/d <sup>c</sup>	6 <sup>b</sup>	normal	0.64±0.13 0.63±0.12	11
Nasmi 2016	25	Iran	mix	35.9±7.6	TSH >4.0 mIU/L	—	50ug/d	2	normal	0.56±0.09 0.57±0.08	11
Ilknur 2014	56	Turkey	mix	41.3±14.5	TSH >4.2 mIU/L	—	25-50 mcg/d	—	normal	0.533±0.112 0.507±0.126	12
Dursun 2007	20	Turkey	female	36±11	TSH >4.2 mIU/L	newly diagnosed	25-100ug/d	5 <sup>b</sup>	normal	0.65±0.99 0.55±0.08	12
Adrees 2009	20	Ireland	female	50±9	—	at least 6 months	100 ± 30 ug/d <sup>c</sup>	18	normal	0.82±0.2 0.71±0.2	10
Dilek 2015	23	Turkey	mix	35.2±10.7	TSH >4.0 mIU/L	at least 6 months	—	6	normal	0.51±0.09 0.46±0.07	11

Abbreviations: TSH, thyroid-stimulating hormone; CIMT, Carotid intima-media thickness; L-T4, levothyroxine.

Mix=including male and female. Age and IMT are expressed as mean± s.d.

<sup>a</sup> median ; <sup>b</sup> mean; <sup>c</sup> mean± s.d; <sup>d</sup> median± interquartile range

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49



TABLE 1(B). Summary of the Characteristics of the Included Studies

Author	TSH assay	Carotid IMT assessment
Monzani	ultrasensitive immunoradiometric assay	both the near and far wall of the right and left common carotid artery and carotid bifurcation(high-resolution ultrasonography)
Soo-Kyung	chemiluminescent immunometric assay	20 mm proximal to the origin of the carotid bulb (high-resolution ultrasonographic system)
Monica	immunochemiluminescence	both the near and far wall of the right and left common artery and the carotid bifurcation.(high-resolution ultrasound imaging)
Levent	Chemiluminescence immunometric assay	approximately 1-cm segment from both the left and right CCA proximal and distal portions (Ultrasonographic images)
Nasmi	–	sonogram B-mode images
Ilknur	electrochemiluminescence immunoassays	Three arterial wall segments of the common carotid artery were measured bilaterally after imaging from a fixed lateral transducer angle and designated (high-resolution B-mode ultrasonography)
Dursun	immunoassay	right and left extracranial carotid arteries: the CCA (1 cm proximal to the dilation of the carotid bulb), the bifurcation (the 1-cm segment proximal to the flow divider), and the internal carotid artery (the 1-cm segment in the internal branch distal to the flow divider).(high-resolution ultrasonography )
Adrees	chemiluminescent immunometric assay	1 cm proximal to the carotid bulb when a satisfactory position was found.(calibrated ultrasound machine)
Dilek	–	ultrasound system

Abbreviations: CCA, common carotid artery.

1  
2  
3  
4 female participants with SCH displayed a non-significant reduction in C-IMT (WMD, -0.04  
5  
6  
7 mm, 95% CI -0.12, 0.03;  $p = 0.256$ ). The heterogeneity was very low ( $I^2 = 0.0\%$ ) (Fig.5).

8  
9  
10 Subgroup analyses were performed using the duration of L-T4 replacement. Except for one reports,  
11  
12  
13 all trials had information on the length of the therapy. There was a significant decrease in C-IMT in  
14  
15  
16 the patients with long-term ( $>6$  months) treatment (WMD, -0.05 mm, 95% CI -0.08, -0.02;  $p=0.001$ ).

17  
18  
19 The outcome showed low heterogeneity ( $I^2 = 12.3\%$ ). A non-significant reduction was found in  
20  
21  
22 C-IMT in the participants with short-term ( $\leq 6$  months) replacement therapy (WMD, -0.02 mm, 95%  
23  
24  
25 CI -0.05, 0.01;  $p=0.214$ ). The heterogeneity was low ( $I^2 = 11.2\%$ ). (Fig. 6).

### 26 27 28 29 30 **Changes in metabolic parameters**

31  
32  
33 Table 2 indicates the changes in metabolic parameters from pre-replacement to  
34  
35  
36 post-treatment. L-T4 therapy was linked to significant reductions in TC, TG, LDL, SBP,  
37  
38  
39 DBP, and LP(a) and decreased FMD. There were no significant changes in BMI, waist  
40  
41  
42 circumference, HDL, ApoA, ApoB and glucose between the pre-treatment and post-therapy  
43  
44  
45 conditions.  
46  
47  
48

### 49 50 51 **Sensitivity and publication bias evaluation**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

We carried out sensitivity analyses by sequentially eliminating one study to probe the change in the total WMD and 95% CI of C-IMT. The results of three RCT sensitivity and publication

For peer review only

**Table 2**

The difference of the changes in metabolic parameters between pre-treatment and post-treatment.

Parameters	No. of patients	WMD (95% CI)	P-value
Waist circumference	66	-0.544(-4.041,2.954)	0.761
BMI	152	-0.231(-1.044,0.582)	0.577
Glucose	48	0.090(-0.109,0.289)	0.375
SBP	109	-9.391(-14.405,-4.377)	0
DBP	109	-5.693(-8.471,-2.916)	0
TC	166	-9.037(-16.635,-1.439)	0.02
TG	166	-9.842(-18.763,-0.921)	0.031
HDL	166	-1.032(-4.059,1.995)	0.504
LDL	166	-14.303(-19.133,-9.472)	0
FMD	39	3.962(2.636,5.289)	0
ApoA	37	-10.092(-23.173,2.989)	0.131
ApoB	37	-7.718(-21.723,6.287)	0.28
LP(a)	34	-9.974(-12.844,-7.103)	0

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA, Apolipoprotein A; ApoB, Apolipoprotein B; Lp(a), lipoprotein(a); WMD, weighted mean difference; CI: confidence interval; FMD, flow-mediated dilatation.

1  
2  
3  
4 bias analyses indicated no variation in the direction of WMD when each publication was  
5  
6  
7 removed. Neither Egger's test ( $p=0.881$ ) nor Begg's test ( $p=0.602$ ) of C-IMT in SCH  
8  
9  
10 manifested publication biases. We also evaluate the sensitivity and publication bias of the  
11  
12  
13 nine self-controlled trial. The results showed that there was only a slight change in the WMD  
14  
15  
16 or 95% CI, and no change in the direction of WMD when any one study was omitted. Egger's  
17  
18  
19 test ( $p=0.378$ ) and Begg's test ( $p=0.602$ ) of C-IMT in SCH manifested publication biases.  
20  
21  
22  
23

## 24 Discussion

25  
26  
27  
28 This meta-analysis indicated that L-T4 has beneficial effects on the development of C-IMT,  
29  
30  
31 particularly in patients of mixed gender. Decreased C-IMT was also observed with longer  
32  
33  
34 treatment ( $>6$  months). L-T4 therapy of SCH participants also resulted in a significant  
35  
36  
37 reduction in TC, TG, LDL, SBP, DBP, LP(a), and FMD.  
38  
39  
40

41  
42 Recent epidemiological surveys found that SCH is an independent risk factors for  
43  
44  
45 cardiovascular disease and atherosclerosis [5, 33]. A meta-analysis of 8 studies including  
46  
47  
48 37,197 subjects indicated that C-IMT is a powerful predictor of prospective vascular  
49  
50  
51 disorders [17]. The American Heart Association/American College of Cardiology guidelines  
52  
53  
54 designated C-IMT along with coronary artery calcium (CAC) score as a class IIa  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 recommendation for cardiovascular risk assessment in asymptomatic adults at intermediate  
5  
6  
7 risk of cardiovascular disease.  
8  
9

10  
11 In the past decades, reports have indicated that SCH is linked to increased C-IMT, but  
12  
13  
14 the findings were inconsistent. Recently, a meta-analysis that incorporated eight  
15  
16  
17 observational trials with 3,602 SCH participants found a strong correlation between SCH and  
18  
19  
20 C-IMT.  
21  
22  
23

24  
25 Many studies reported L-T4 therapy had beneficial effects on cardiovascular system in  
26  
27  
28 SCH patients. L-T4 therapy had beneficial effects an observational analysis with long-term  
29  
30  
31 follow-up for 8 years from the English general medical practitioner research database found  
32  
33  
34 that L-T4 therapy was linked with lower CHD morbidity in moderately old (<70 years) and  
35  
36  
37 middle-aged SCH patients [34]. Several interventional RCT indicated that L-T4 therapy to  
38  
39  
40 restore euthyroidism improved most functional surrogate markers and coronary artery (CV)  
41  
42  
43 structure [9, 16, 35, 36]. Other trials revealed favourable changes in cardiac contractility and  
44  
45  
46 systolic time interval using L-T4 replacement [37]. Various reports also showed that L-T4  
47  
48  
49 treatment of participants with mild-SCH had beneficial effects on diastolic function during  
50  
51  
52 rest or at exercise, cardiac systolic function, endothelial function, systemic vessel resistance,  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 cardiac preload, and arterial stiffness [18, 35, 38]. Two meta-analyses demonstrated that L-T4  
5  
6  
7 therapy had beneficial effects on serum lipid concentration in SCH patients [6, 39].  
8  
9

10 The mechanism underlying the L-T4-mediated decrease in C-IMT has not been fully  
11  
12 elucidated. In SCH, the increased TSH is the only prominent change, and increased TSH can  
13  
14 bind with the TSH receptor (TSHR) to perform its function. Balzan et al. [40] revealed that  
15  
16 micro-vascular endothelial cells produce TSHR, which may help to elucidate this relationship.  
17  
18 Recently, Tian et al. [41] published a study to identify the potential function of the TSHR and  
19  
20 showed that increased TSH aggravated endothelial dysfunction. However, L-T4 can control  
21  
22 the elevated TSH by reversing above-mentioned changes to reduce the mean C-IMT.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 Consistent with these publications, we concluded that the mechanism underlying the  
35  
36 L-T4 therapy-mediated decrease in mean C-IMT of SCH patients is complex. In addition to  
37  
38 the mechanism of TSHR, hyperlipidaemia and blood pressure may also contribute to the  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
reduction.

In a large cross-sectional study, an increase of 1.0 mU/l in serum TSH was associated  
with an average increase in TC values of 0.09 mm in women [37]. There was a decrease in  
both TC and LDL in specific groups of patients (baseline serum TSH >12 mU/l) during one

1  
2  
3  
4 year of L-T4 substitution therapy reported by Meier et al. [42]. A decrease in LDL of 0.41  
5  
6  
7  
8 mmol/l and TC of 0.47 mmol/l was observed by Caraccio et al. [43], and the effects were  
9  
10  
11 noted in patients (mostly premenopausal women) with mildly elevated TSH (<10 mU/l) and  
12  
13  
14 Hashimoto's thyroiditis. However, there is no agreement on the effect of L-T4 substitution  
15  
16  
17 treatment on lipid changes [37, 42]. Six out of 13 papers in a systemic review reported that  
18  
19  
20 L-T4 treatment improved TC and LDL [6]. A RCT trial with the same conclusion further  
21  
22  
23 supported this hypothesis [19].  
24  
25  
26

27  
28       Among four markers of hyperlipidaemia (TC, TG, LDL, HDL), we observed  
29  
30  
31 non-significant differences only in HDL between pre-treatment and post-replacement  
32  
33  
34 conditions, which is supported by previous study with similar findings [44]. Reports by  
35  
36  
37 Kannel et al. [45] and Lewington et al. [46] showed that the TC/HDL ratio is more important  
38  
39  
40 in the progress of coronary heart disease than either TC or HDL alone. Although HDL  
41  
42  
43 concentration was not changed after restoration of euthyroidism by L-T4 replacement in SCH  
44  
45  
46 patients in our study, L-T4 treatment altered the TC/HDL ratio.  
47  
48  
49

50  
51  
52       A previous study found that higher TSH, TC, and LDL are associated with increased  
53  
54  
55 endothelial dysfunction in SCH patients [47]. The Helsinki Heart Study reported that a 7%  
56  
57  
58



1  
2  
3  
4 reduction in LDL levels was related to a 15% decrease in the coronary heart disease  
5  
6  
7 incidence [48], indicating a significant benefit of L-T4 supplementation. A possible  
8  
9  
10 explanation is that SCH can cause endothelial dysfunction because of a decrease in NO  
11  
12  
13 availability, which is partly independent of dyslipidaemia, and L-T4 supplementation can  
14  
15  
16 reverse endothelial dysfunction [9]. Hyperlipidaemia promotes endothelial dysfunction  
17  
18  
19 because it can inhibit the NO synthesis pathway in endothelial cells [49]. Thus, we found that  
20  
21  
22 SCH not only results in endothelial dysfunction but is also an independent risk factor of  
23  
24  
25 dyslipidaemia; then, dyslipidaemia further amplifies endothelial dysfunction. L-T4 treatment  
26  
27  
28 of SCH patients can reduce these effects.  
29  
30  
31  
32

33  
34  
35 A meta-analysis showed that blood pressure was an independent risk factor for C-IMT  
36  
37  
38 [48]. Recently, a meta-analysis demonstrated that SCH is linked to higher SBP and DBP  
39  
40  
41 levels [50]. Faber showed that a drop in BP (-6%) appeared followed increased cardiac output  
42  
43  
44 (+14%) after 4 months of L-T4 supplementation [51]. Restoration to euthyroidism by 6  
45  
46  
47 months of L-T4 therapy decreased SBP in SCH subjects as shown by Anagnostis et al. [52].  
48  
49  
50 However, results showing that L-T4 treatment reduced BP have not been confirmed. Another  
51  
52  
53 study found that L-T4 supplementation non-significantly improved BP [30].  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 We know little about the mechanism of SCH-associated hypertension; nevertheless,  
5  
6  
7  
8 hypothyroidism increases vascular resistance, enhances blood pressure, salt sensitivity and  
9  
10  
11 abnormal sodium metabolism, which may promote the development of hypertension.  
12

13  
14 For the subgroup of short duration ( $\leq 6$  months), an insignificant difference of C-IMT  
15  
16  
17 was observed after treatment. Meanwhile, mean C-IMT in SCH subjects undergoing  
18  
19  
20 long-term treatment significantly increased compared to that in the pre-treatment condition.  
21  
22  
23 This phenomenon was confirmed in our clinical observation. The major reason is that the  
24  
25  
26 duration of treatment is too short to improve C-IMT. The rate of progression of IMT in the  
27  
28  
29 common carotid artery was approximately 0.01 mm/year.  
30  
31  
32

33  
34  
35 For stratification by gender, we did not find a significant difference in female patients  
36  
37  
38 between pre-replacement and post-replacement. Meanwhile, for the mixed subgroup, mean  
39  
40  
41 C-IMT was significantly reduced after treatment. Only 3 out of 9 studies evaluated female  
42  
43  
44 SCH patients. Due to the lack of data, both small sample size and potential confounding  
45  
46  
47 factors can prevent the linkage between C-IMT degree and L-T4 treatment in SCH female  
48  
49  
50 patients.  
51  
52

53  
54  
55 In conclusion, our study suggests that C-IMT in SCH patients can be reversed by L-T4  
56  
57

1  
2  
3  
4 replacement. Hyperlipidaemia and hypertension may improve after L-T4 therapy. Therefore,  
5  
6  
7  
8 L-T4 supplementation can prevent or inhibit the progression of atherosclerosis, at least in  
9  
10  
11 SCH patients. RCTs with longer treatment durations are needed to confirm these findings.  
12

#### 13 14 contributorship statement

15  
16  
17 Zhao Tong and Chen Baomin made search strategies, searched papers from  
18  
19  
20  
21 databases, assessed of study quality ,independently extracted data from the papers  
22  
23  
24 and wrote the paper Wang Haoyu as a third reviewer was asked for advice,If there was  
25  
26  
27 disagreement.Zhou Yingying, Wang Xinyi and Zhang Yuanyuan Participated in the  
28  
29  
30  
31 revision of the paper.  
32

#### 33 34 competing interests statement

35  
36  
37  
38 The author denies that he has any intention to obtain any financial interests.  
39  
40

#### 41 42 Funding

43  
44  
45 There are no funders to report for this submission  
46  
47

#### 48 49 Data Sharing Statement

50  
51  
52 No additional unpublished data are available  
53  
54  
55  
56  
57  
58

## References

1. Cooper DS. Clinical practice. Subclinical hypothyroidism. *N Engl J Med*. 2001;345(4):260-5. Epub 2001/07/28. doi: 10.1056/nejm200107263450406. PubMed PMID: 11474665.
2. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. *Annals of internal medicine*. 1984;101(1):18-24. Epub 1984/07/01. PubMed PMID: 6428290.
3. Monzani F, Caraccio N, Del Guerra P, Casolaro A, Ferrannini E. Neuromuscular symptoms and dysfunction in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy. *Clin Endocrinol (Oxf)*. 1999;51(2):237-42. Epub 1999/09/01. PubMed PMID: 10468996.
4. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. *The Journal of clinical endocrinology and metabolism*. 2003;88(6):2438-44. Epub 2003/06/06. doi: 10.1210/jc.2003-030398. PubMed PMID: 12788839.

1  
2  
3  
4 5. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical  
5  
6  
7  
8 hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in  
9  
10  
11 elderly women: the Rotterdam Study. *Annals of internal medicine*. 2000;132(4):270-8. Epub  
12  
13  
14 2000/02/19. PubMed PMID: 10681281.

15  
16  
17  
18 6. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of  
19  
20  
21 thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative  
22  
23  
24 review of the literature. *The Journal of clinical endocrinology and metabolism*.  
25  
26  
27 2000;85(9):2993-3001. Epub 2000/09/22. doi: 10.1210/jcem.85.9.6841. PubMed PMID:  
28  
29  
30  
31 10999775.

32  
33  
34  
35 7. Liu D, Jiang F, Shan Z, Wang B, Wang J, Lai Y, et al. A cross-sectional survey of  
36  
37  
38 relationship between serum TSH level and blood pressure. *Journal of human hypertension*.  
39  
40  
41 2010;24(2):134-8. Epub 2009/06/26. doi: 10.1038/jhh.2009.44. PubMed PMID: 19554027;  
42  
43  
44  
45 PubMed Central PMCID: PMC3011094.

46  
47  
48 8. Yang L, Lv X, Yue F, Wei D, Liu W, Zhang T. Subclinical hypothyroidism and the risk of  
49  
50  
51 metabolic syndrome: A meta-analysis of observational studies. *Endocr Res*.  
52  
53  
54  
55 2016;41(2):158-65. Epub 2016/03/05. doi: 10.3109/07435800.2015.1108332. PubMed PMID:  
56  
57  
58

1  
2  
3  
4 26934475.  
5  
6

7 9. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired  
8  
9  
10 endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of  
11  
12 levothyroxine therapy. *The Journal of clinical endocrinology and metabolism*.  
13  
14 2003;88(8):3731-7. Epub 2003/08/14. doi: 10.1210/jc.2003-030039. PubMed PMID:  
15  
16 12915662.  
17  
18  
19  
20  
21  
22

23  
24 10. Vyakaranam S, Vanaparthi S, Nori S, Palarapu S, Bhongir AV. Study of Insulin  
25  
26  
27 Resistance in Subclinical Hypothyroidism. *International journal of health sciences and*  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
research. 2014;4(9):147-53. Epub 2015/01/13. PubMed PMID: 25580384; PubMed Central  
PMCID: PMCPmc4286301.

11. Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH. Carotid intima-media thickness in  
patients with subclinical hypothyroidism: a meta-analysis. *Atherosclerosis*.  
2013;227(1):18-25. Epub 2012/11/20. doi: 10.1016/j.atherosclerosis.2012.10.070. PubMed  
PMID: 23159101.

12. Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ, Ozden M, Duman C. Hemostatic  
system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism.

1  
2  
3  
4 Thyroid : official journal of the American Thyroid Association. 2003;13(10):971-7. Epub  
5  
6  
7 2003/11/13. doi: 10.1089/105072503322511382. PubMed PMID: 14611707.  
8  
9

10  
11 13. Cebeci E, Oner FA, Usta M, Yurdakul S, Erguney M. Evaluation of oxidative stress, the  
12  
13 activities of paraoxonase and arylesterase in patients with subclinic hypothyroidism. Acta  
14  
15 bio-medica : Atenei Parmensis. 2011;82(3):214-22. Epub 2012/07/13. PubMed PMID:  
16  
17 22783718.  
18  
19  
20  
21  
22  
23

24  
25 14. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and  
26  
27 event prediction. The American journal of cardiology. 2002;90(10c):181-211. Epub  
28  
29 2002/12/03. PubMed PMID: 12459422.  
30  
31  
32  
33

34  
35 15. Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E. Carotid artery intima-media  
36  
37 thickness measured by ultrasonography in normal clinical practice correlates well with  
38  
39 atherosclerosis risk factors. Stroke; a journal of cerebral circulation. 2000;31(10):2426-30.  
40  
41  
42  
43  
44  
45 Epub 2000/10/07. PubMed PMID: 11022075.  
46  
47

48  
49 16. Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Viridis A, et al. Effect of  
50  
51 levothyroxine replacement on lipid profile and intima-media thickness in subclinical  
52  
53 hypothyroidism: a double-blind, placebo- controlled study. The Journal of clinical  
54  
55  
56  
57  
58

1  
2  
3  
4 endocrinology and metabolism. 2004;89(5):2099-106. Epub 2004/05/06. doi:  
5  
6  
7 10.1210/jc.2003-031669. PubMed PMID: 15126526.  
8  
9

10  
11 17. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical  
12  
13 cardiovascular events with carotid intima-media thickness: a systematic review and  
14  
15 meta-analysis. *Circulation*. 2007;115(4):459-67. Epub 2007/01/24. doi:  
16  
17 10.1161/circulationaha.106.628875. PubMed PMID: 17242284.  
18  
19  
20  
21  
22

23  
24 18. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of  
25  
26 L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in  
27  
28 subclinical hypothyroidism: randomized, crossover trial. *The Journal of clinical*  
29  
30  
31  
32 endocrinology and metabolism. 2007;92(5):1715-23. Epub 2007/02/15. doi:  
33  
34  
35 10.1210/jc.2006-1869. PubMed PMID: 17299073.  
36  
37  
38  
39

40  
41 19. Andersen MN, Olsen AM, Madsen JC, Faber J, Torp-Pedersen C, Gislason GH, et al.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Levothyroxine Substitution in Patients with Subclinical Hypothyroidism and the Risk of  
Myocardial Infarction and Mortality. *PLoS One*. 2015;10(6):e0129793. Epub 2015/06/13. doi:  
10.1371/journal.pone.0129793. PubMed PMID: 26069971; PubMed Central PMCID:  
PMCPmc4466400.



1  
2  
3  
4 20. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a  
5  
6  
7 summary of the evidence for the U.S. Preventive Services Task Force. *Annals of internal*  
8  
9  
10 medicine. 2004;140(2):128-41. Epub 2004/01/22. PubMed PMID: 14734337.

11  
12  
13  
14 21. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid  
15  
16  
17 disease: scientific review and guidelines for diagnosis and management. *Jama*.  
18  
19  
20 2004;291(2):228-38. Epub 2004/01/15. doi: 10.1001/jama.291.2.228. PubMed PMID:  
21  
22  
23  
24 14722150.

25  
26  
27  
28 22. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index  
29  
30  
31 for non-randomized studies (minors): development and validation of a new instrument. *ANZ*  
32  
33  
34 *journal of surgery*. 2003;73(9):712-6. Epub 2003/09/06. PubMed PMID: 12956787.

35  
36  
37  
38 23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in  
39  
40  
41 meta-analyses. *BMJ (Clinical research ed)*. 2003;327(7414):557-60. Epub 2003/09/06. doi:  
42  
43  
44 10.1136/bmj.327.7414.557. PubMed PMID: 12958120; PubMed Central PMCID:  
45  
46  
47 PMCPmc192859.

48  
49  
50  
51  
52 24. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and  
53  
54  
55 dealing with publication and other biases in meta-analysis. *BMJ (Clinical research ed)*.  
56  
57  
58

1  
2  
3  
4 2001;323(7304):101-5. Epub 2001/07/14. PubMed PMID: 11451790; PubMed Central  
5  
6  
7  
8 PMCID: PMC1120714.

9  
10  
11 25. Cabral MD, Teixeira P, Soares D, Leite S, Salles E, Waisman M. Effects of thyroxine  
12  
13 replacement on endothelial function and carotid artery intima-media thickness in female  
14  
15 patients with mild subclinical hypothyroidism. Clinics (Sao Paulo). 2011;66(8):1321-8. doi:  
16  
17  
18 10.1590/S1807-59322011000800003. PubMed PMID: 21915478; PubMed Central PMCID:  
19  
20  
21  
22  
23  
24  
25 PMCPMC3161206.

26  
27  
28 26. Duman D, Demirtunc R, Sahin S, Esertas K. The effects of simvastatin and  
29  
30  
31 levothyroxine on intima-media thickness of the carotid artery in female normolipemic  
32  
33  
34 patients with subclinical hypothyroidism: a prospective, randomized-controlled study. J  
35  
36  
37  
38 Cardiovasc Med (Hagerstown). 2007;8(12):1007-11. doi: 10.2459/JCM.0b013e3282f03bc1.  
39  
40  
41  
42 PubMed PMID: 18163011.

43  
44  
45 27. Unsal IO, Topaloglu O, Cakir E, Bozkurt NC, Karbek B, Gungunes A, et al. Effect of  
46  
47  
48 L-thyroxin therapy on thyroid volume and carotid artery intima-media thickness in the  
49  
50  
51  
52 patients with subclinical hypothyroidism. J Med Disord. 2014;2(1):1. doi:  
53  
54  
55  
56 10.7243/2053-3659-2-1.

1  
2  
3  
4 28. Kebapcilar L, Comlekci A, Tuncel P, Solak A, Secil M, Gencel O, et al. Effect of  
5  
6  
7  
8 levothyroxine replacement therapy on paraoxonase-1 and carotid intima-media thickness in  
9  
10  
11 subclinical hypothyroidism. *Med Sci Monit.* 2010;16(1):CR41-7. PubMed PMID: 20037493.

12  
13  
14 29. Adrees M, Gibney J, El-Saeity N, Boran G. Effects of 18 months of l-T4 replacement in  
15  
16  
17  
18 women with subclinical hypothyroidism. *Clinical endocrinology.* 2009;71(2):298-303. doi:  
19  
20  
21 10.1111/j.1365-2265.2008.03509.x.

22  
23  
24 30. Yazıcı D, Özben B, Toprak A, Yavuz D, Aydın H, Tarçın Ö, et al. Effects of restoration of  
25  
26  
27  
28 the euthyroid state on epicardial adipose tissue and carotid intima media thickness in  
29  
30  
31 subclinical hypothyroid patients. *Endocrine.* 2014;48(3):909-15. doi:  
32  
33  
34 10.1007/s12020-014-0372-1.

35  
36  
37  
38 31. Niknam N, Khalili N, Khosravi E, Nourbakhsh M. Endothelial dysfunction in patients  
39  
40  
41 with subclinical hypothyroidism and the effects of treatment with levothyroxine. *Advanced*  
42  
43  
44  
45  
46  
47  
48  
49 biomedical research. 2016;5:38. Epub 2016/04/22. doi: 10.4103/2277-9175.178783. PubMed  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
PMID: 27099851; PubMed Central PMCID: PMC4815523.

32. Kim SK, Kim SH, Park KS, Park SW, Cho YW. Regression of the increased common  
carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone

1  
2  
3  
4 replacement. *Endocr J.* 2009;56(6):753-8. Epub 2009/06/10. PubMed PMID: 19506325.  
5  
6

7 33. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, et al.  
8  
9  
10 Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. *Arch Intern Med.*  
11  
12  
13  
14 2005;165(21):2467-72. Epub 2005/11/30. doi: 10.1001/archinte.165.21.2467. PubMed PMID:  
15  
16  
17 16314542.  
18  
19

20  
21 34. Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine treatment of subclinical  
22  
23  
24 hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. *Arch Intern Med.*  
25  
26  
27  
28 2012;172(10):811-7. Epub 2012/04/25. doi: 10.1001/archinternmed.2012.1159. PubMed  
29  
30  
31 PMID: 22529180.  
32  
33

34  
35 35. Biondi B, Fazio S, Palmieri EA, Carella C, Panza N, Cittadini A, et al. Left ventricular  
36  
37  
38 diastolic dysfunction in patients with subclinical hypothyroidism. *The Journal of clinical*  
39  
40  
41 *endocrinology and metabolism.* 1999;84(6):2064-7. Epub 1999/06/18. doi:  
42  
43  
44  
45 10.1210/jcem.84.6.5733. PubMed PMID: 10372711.  
46  
47

48  
49 36. Monzani F, Di Bello V, Caraccio N, Bertini A, Giorgi D, Giusti C, et al. Effect of  
50  
51  
52 levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind,  
53  
54  
55 placebo-controlled study. *The Journal of clinical endocrinology and metabolism.*  
56  
57  
58

1  
2  
3  
4 2001;86(3):1110-5. Epub 2001/03/10. doi: 10.1210/jcem.86.3.7291. PubMed PMID:  
5  
6  
7 11238494.  
8

9  
10  
11 37. Efstathiadou Z, Bitsis S, Milionis HJ, Kukuvtis A, Bairaktari ET, Elisaf MS, et al. Lipid  
12  
13  
14 profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J  
15  
16  
17 Endocrinol. 2001;145(6):705-10. Epub 2001/11/27. PubMed PMID: 11720894.  
18

19  
20  
21 38. Xiang GD, He YS, Zhao LS, Hou J, Yue L, Xiang HJ. Impairment of  
22  
23  
24 endothelium-dependent arterial dilation in Hashimoto's thyroiditis patients with euthyroidism.  
25  
26  
27 Clin Endocrinol (Oxf). 2006;64(6):698-702. Epub 2006/05/23. doi:  
28  
29  
30 10.1111/j.1365-2265.2006.02531.x. PubMed PMID: 16712674.  
31  
32

33  
34  
35 39. Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on  
36  
37  
38 hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of  
39  
40  
41 intervention studies. Clin Endocrinol (Oxf). 1996;44(6):643-9. Epub 1996/06/01. PubMed  
42  
43  
44 PMID: 8759176.  
45

46  
47  
48 40. Balzan S, Del Carratore R, Nicolini G, Beffy P, Lubrano V, Forini F, et al. Proangiogenic  
49  
50  
51 effect of TSH in human microvascular endothelial cells through its membrane receptor. The  
52  
53  
54 Journal of clinical endocrinology and metabolism. 2012;97(5):1763-70. Epub 2012/03/16.  
55  
56

1  
2  
3  
4 doi: 10.1210/jc.2011-2146. PubMed PMID: 22419707.  
5  
6

7  
8 41. Tian L, Zhang L, Liu J, Guo T, Gao C, Ni J. Effects of TSH on the function of human  
9  
10 umbilical vein endothelial cells. *Journal of molecular endocrinology*. 2014;52(2):215-22.  
11  
12  
13  
14 Epub 2014/01/22. doi: 10.1530/jme-13-0119. PubMed PMID: 24444496.  
15  
16

17  
18 42. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, et al.  
19  
20  
21 TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in  
22  
23 subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study).  
24  
25  
26  
27  
28 The *Journal of clinical endocrinology and metabolism*. 2001;86(10):4860-6. Epub  
29  
30  
31 2001/10/16. doi: 10.1210/jcem.86.10.7973. PubMed PMID: 11600554.  
32  
33

34  
35 43. Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism:  
36  
37 response to levothyroxine replacement, a randomized placebo-controlled study. *The Journal*  
38  
39  
40  
41  
42 of *clinical endocrinology and metabolism*. 2002;87(4):1533-8. Epub 2002/04/05. doi:  
43  
44  
45 10.1210/jcem.87.4.8378. PubMed PMID: 11932277.  
46  
47

48  
49 44. Asranna A, Taneja RS, Kulshreshta B. Dyslipidemia in subclinical hypothyroidism and  
50  
51  
52 the effect of thyroxine on lipid profile. *Indian J Endocrinol Metab*. 2012;16(Suppl 2):S347-9.  
53  
54  
55  
56 Epub 2013/04/09. doi: 10.4103/2230-8210.104086. PubMed PMID: 23565423; PubMed  
57  
58

1  
2  
3  
4 Central PMCID: PMCPMC3603071.  
5  
6

7  
8 45. Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ. Usefulness of the  
9  
10 triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for  
11  
12 predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring  
13  
14 Cohort). The American journal of cardiology. 2008;101(4):497-501. Epub 2008/03/04. doi:  
15  
16 10.1016/j.amjcard.2007.09.109. PubMed PMID: 18312765; PubMed Central PMCID:  
17  
18 PMCPmc3753679.  
19  
20  
21  
22  
23  
24  
25  
26

27  
28 46. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood  
29  
30 cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of  
31  
32 individual data from 61 prospective studies with 55,000 vascular deaths. Lancet.  
33  
34 2007;370(9602):1829-39. Epub 2007/12/07. doi: 10.1016/s0140-6736(07)61778-4. PubMed  
35  
36 PMID: 18061058.  
37  
38  
39  
40  
41  
42  
43  
44

45 47. Shavdatuashvili T. Lipoprotein profile and endothelial function in patients with  
46  
47 subclinical and overt hypothyroidism. Georgian medical news. 2005;129:57-60. Epub  
48  
49 2006/01/31. PubMed PMID: 16444032.  
50  
51  
52  
53

54  
55 48. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, et al. Carotid  
56  
57  
58

1  
2  
3  
4 intima-media thickness and antihypertensive treatment: a meta-analysis of randomized  
5  
6  
7 controlled trials. *Stroke; a journal of cerebral circulation*. 2006;37(7):1933-40. Epub  
8  
9  
10 2006/06/10. doi: 10.1161/01.str.0000227223.90239.13. PubMed PMID: 16763185.

11  
12  
13  
14 49. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for  
15  
16  
17 endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.  
18  
19  
20 *Circulation*. 1999;99(24):3092-5. Epub 1999/06/22. PubMed PMID: 10377069.

21  
22  
23  
24 50. Cai Y, Ren Y, Shi J. Blood pressure levels in patients with subclinical thyroid dysfunction:  
25  
26  
27 a meta-analysis of cross-sectional data. *Hypertension research : official journal of the*  
28  
29  
30 *Japanese Society of Hypertension*. 2011;34(10):1098-105. Epub 2011/07/29. doi:  
31  
32 10.1038/hr.2011.91. PubMed PMID: 21796125.

33  
34  
35  
36  
37  
38 51. Faber J, Petersen L, Wiinberg N, Schifter S, Mehlsen J. Hemodynamic changes after  
39  
40  
41 levothyroxine treatment in subclinical hypothyroidism. *Thyroid : official journal of the*  
42  
43  
44 *American Thyroid Association*. 2002;12(4):319-24. Epub 2002/05/30. doi:  
45  
46  
47 10.1089/10507250252949450. PubMed PMID: 12034057.

48  
49  
50  
51  
52 52. Anagnostis P, Efstathiadou ZA, Slavakis A, Selalmatzidou D, Poulasouchidou M,  
53  
54  
55 Katergari S, et al. The effect of L-thyroxine substitution on lipid profile, glucose homeostasis,  
56  
57  
58



1  
2  
3  
4 inflammation and coagulation in patients with subclinical hypothyroidism. *Int J Clin Pract.*

5  
6  
7 2014;68(7):857-63. Epub 2014/02/20. doi: 10.1111/ijcp.12394. PubMed PMID: 24548294.

8  
9  
10  
11  
12 Fig.1. Process of study selection.

13  
14  
15 Abbreviations: IMT: intima-media thickness; SCH: subclinical hypothyroidism

16  
17  
18  
19 Fig.2. Quality assessment of the included studies. Risk of bias graph (A); risk of bias summary (B).

20  
21  
22  
23 Fig.3. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals for improvement  
24  
25  
26 in carotid intima-media thickness comparing L-T4 treatment to the control in a fixed effects model.

27  
28  
29  
30 Fig.4. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals compared the  
31  
32  
33 value of C-IMT before replacement and after treatment in a fixed effects model.

34  
35  
36 Fig.5. Subgroup analyses of carotid intima-media thickness changes based on gender in a fixed effects model.

37  
38  
39  
40 Fig.6. Subgroup analyses of carotid intima-media thickness changes based on duration of L-T4 replacement in a  
41  
42  
43 fixed effects model.

44  
45  
46 Long= duration of L-T4 replacement >6 months

47  
48  
49 Short= duration of L-T4 replacement ≤6 months




Fig.1. Process of study selection.

113x162mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Fig.2. Quality assessment of the included studies. Risk of bias graph (A).

5x2mm (600 x 600 DPI)

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Dursun Duman 2007	+	+	+	+	-	+	?
F. MONZANI 2004	+	?	-	-	+	+	+
Monica Dias Cabral 2011	+	+	+	+	+	+	?

Fig.2. Quality assessment of the included studies. risk of bias summary (B)

99x123mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.3. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals for improvement in carotid intima-media thickness comparing L-T4 treatment to the control in a fixed effects model.

31x20mm (600 x 600 DPI)

View only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.4. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals compared the value of C-IMT before replacement and after treatment in a fixed effects model.

13x9mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.5.Subgroup analyses of carotid intima-media thickness changes based on gender in a fixed effects model.

119x95mm (600 x 600 DPI)

only




Fig.6.Subgroup analyses of carotid intima-media thickness changes based on duration of L-T4 replacement in a fixed effects model.

Long= duration of L-T4 replacement>6 months  
 Short= duration of L-T4 replacement≤6 months

39x31mm (600 x 600 DPI)

only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.S1 Begg's funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in RCT studies

13x8mm (600 x 600 DPI)

er review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.S2 Begg's funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in self-controlled studies

14x9mm (600 x 600 DPI)

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.S3 Funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in RCT studies

14x10mm (600 x 600 DPI)

review only




Fig.S4 Funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in self-controlled studies

14x10mm (600 x 600 DPI)

review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.S5 Sensitivity analysis of the RCT studies included in the meta-analysis. The figure shows the WMD obtained by combined analysis of the remaining studies after the successive exclusion of each study individually. The excluded study is listed on the left, and the corresponding horizontal lines indicate the WMD and CI obtained by re-calculation after its exclusion. The CI for the overall meta-analysis of the studies is indicated by two vertical lines.

13x8mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.S6 Sensitivity analysis of the self-controlled studies included in the meta-analysis. The figure shows the WMD obtained by combined analysis of the remaining studies after the successive exclusion of each study individually. The excluded study is listed on the left, and the corresponding horizontal lines indicate the WMD and CI obtained by re-calculation after its exclusion. The CI for the overall meta-analysis of the studies is indicated by two vertical lines.

14x9mm (600 x 600 DPI)

Review only

1  
2  
3  
4 Fig.S1 Begg's funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on  
5  
6 C-IMT in RCT studies  
7

8  
9 Fig.S2 Begg's funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on  
10  
11 C-IMT in self-controlled studies  
12

13  
14 Fig.S3 Funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in  
15  
16 RCT studies  
17

18  
19 Fig.S4 Funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in  
20  
21 self-controlled studies  
22

23  
24 Fig.S5 Sensitivity analysis of the RCT studies included in the meta-analysis. The figure shows the  
25  
26 WMD obtained by combined analysis of the remaining studies after the successive exclusion of each  
27  
28 study individually. The excluded study is listed on the left, and the corresponding horizontal lines  
29  
30 indicate the WMD and CI obtained by re-calculation after its exclusion. The CI for the overall  
31  
32 meta-analysis of the studies is indicated by two vertical lines.  
33

34  
35  
36 Fig.S6 Sensitivity analysis of the self-controlled studies included in the meta-analysis. The figure  
37  
38 shows the WMD obtained by combined analysis of the remaining studies after the successive exclusion  
39  
40 of each study individually. The excluded study is listed on the left, and the corresponding horizontal  
41  
42 lines indicate the WMD and CI obtained by re-calculation after its exclusion. The CI for the overall  
43  
44 meta-analysis of the studies is indicated by two vertical lines.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5-6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8-9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ for each meta-analysis).	9





# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8-9
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	11
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	17
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	15
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	18
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	18
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	18
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19-20
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	3
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	25
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	25

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: A meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016053.R1
Article Type:	Research
Date Submitted by the Author:	02-Aug-2017
Complete List of Authors:	Zhao, Tong; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Chen, Baomin; First Affiliated Hospital, Chinese Medical University, liver and gall surgical Zhou, Yingying; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Wang, Xinyi; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Zhang, Yuanyuan; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Wang, Haoyu; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Shan, Zhongyan; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Nutrition and metabolism, Cardiovascular medicine
Keywords:	subclinical hypothyroidism, carotid intima-media thickness, thyroxin, cardiovascular risk

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Effect of levothyroxine on the progression of carotid intima-media**  
5  
6  
7 **thickness in subclinical hypothyroidism patients: A meta-analysis**  
8  
9

10  
11 Zhao Tong, Chen Baomin, Zhou Yingying, Wang xinyi, Zhang yuanyuan, Wang haoyu, Shan

12  
13  
14  
15  
16 Zhongyan

17  
18  
19  
20 *Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning*

21  
22  
23 *Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China*

24  
25  
26 *Medical University, No.155 Nanjing North Street, Shenyang 110001, China*  
27

28  
29  
30 the email address of the corresponding author

31  
32  
33 *Zhao, Tong* [cmu\\_zhaotong@163.com](mailto:cmu_zhaotong@163.com)

34  
35  
36  
37 *Chen, Baomin* [cbm19910330@163.com](mailto:cbm19910330@163.com)

38  
39  
40  
41 *Zhou, Yingying* [18937856536@163.com](mailto:18937856536@163.com)

42  
43  
44  
45 *Wang, Xinyi* [wangxinyi4125@163.com](mailto:wangxinyi4125@163.com)

46  
47  
48 *Zhang, Yuanyuan* [yuan-anpo@163.com](mailto:yuan-anpo@163.com)

49  
50  
51 *Wang, Haoyu* [why\\_endocrinology@foxmail.com](mailto:why_endocrinology@foxmail.com)

52  
53  
54  
55 *Shan, Zhongyan (Corresponding Author)* [shanzhongyan@medmail.com.cn](mailto:shanzhongyan@medmail.com.cn)

56  
57 **Abstract**

58  
59 1 / 30  
60

1  
2  
3  
4 **Background and aims:** Subclinical hypothyroidism (SCH) has been associated with  
5  
6  
7 increased carotid intima-media thickness (C-IMT) in recent studies, but the effects of  
8  
9  
10 levothyroxine (L-T4) on C-IMT in SCH patients are still controversial. The aim of the current  
11  
12  
13 study was to evaluate the effect of L-T4 therapy on endothelial function as determined by  
14  
15  
16  
17 C-IMT in patients with SCH.

18  
19  
20 **Methods:** Prior to July 2016, we searched the PUBMED, EMBASE, COCHRANE  
21  
22  
23 LIBRARY and GOOGLE SCHOLAR databases we selected published randomized  
24  
25  
26 controlled trials (RCTs) and self-controlled trials.  
27  
28

29  
30  
31 **Results:** Three RCTs with 117 patients were considered suitable for the meta-analysis. The  
32  
33  
34 results of the meta-analysis indicated that L-T4 significantly decreased the development of  
35  
36  
37 C-IMT [weighted mean difference (WMD), -0.05 mm, 95% CI -0.08, -0.01; p = 0.025]. We  
38  
39  
40 also analysed 9 studies (self-controlled trials) with 247 patients and extracted the IMT of  
41  
42  
43 SCH patients before and after L-T4 treatment. After L-T4 therapy, the pooled estimate of the  
44  
45  
46 WMD of decreased C-IMT was -0.04 mm (95% CI -0.07, -0.02; p = 0.05). Subgroup  
47  
48  
49 analysis showed that L-T4 therapy was associated with a decrease in C-IMT among patients  
50  
51  
52 of mixed genders (WMD, -0.03 mm, 95% CI -0.06, -0.01; p = 0.145). L-T4 therapy was  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 associated with a decrease in C-IMT among female patients (WMD, -0.07 mm, 95% CI -0.14,  
5  
6  
7 -0.01; p = 0.186). Longer treatment (>6 months) also resulted in a significant decrease in  
8  
9  
10  
11 C-IMT (WMD, -0.05 mm, 95% CI -0.08, -0.02; p=0.335).  
12  
13

14 **Conclusion:** This meta-analysis indicates that L-T4 treatment of SCH patients can reduce  
15  
16  
17 C-IMT, possibly as a result of the reduction of TC, TG, LDL-C, SBP, DBP, LP(a), and FMD.  
18  
19  
20  
21 Decreased C-IMT was observed in SCH patients after long-term (>6 months) L-T4 treatment.  
22  
23  
24  
25 RCTs with large samples are needed to verify these observations.  
26  
27

#### 28 ***Strengths and limitations of this study:***

##### 29 ***Strengths***

30  
31  
32 A strong quality evidence on the effect of L-T4 therapy in SCH patients is preformed.  
33  
34  
35  
36 Methodology, according to the different types of original literature, we used different  
37  
38  
39  
40 method of statistical analysis and study quality evaluation. According to different  
41  
42  
43  
44 heterogeneity, we adopt different effect model. This embodies the rigor of methodology  
45  
46  
47  
48 Furthermore, we analysis other metabolic parameters to better explain to effect of L-T4  
49  
50  
51  
52 therapy in SCH.

##### 53 ***Limitations***

1  
2  
3  
4 The number of including studies was small, and the overall population of these trials was not  
5  
6  
7 large. Meta analysis has moderate heterogeneity. Difficult assessment of the potential  
8  
9  
10 publication bias mainly due to the previous two factors. Additionally, we did not perform  
11  
12  
13 subgroup analysis according to the level of TSH (the cutoff value is 10 mU/ml to distinguish  
14  
15  
16 mild SCH and severe SCH) because the original studies did not perform analyses according  
17  
18  
19 to the level of TSH. Finally, we did not perform subgroup analysis by mean age (>65 or <65  
20  
21  
22 years) because all participants' mean age was below 65 years.  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 **Keywords:** subclinical hypothyroidism; carotid intima-media thickness; thyroxin;  
33  
34  
35 cardiovascular risk  
36  
37  
38  
39

## 40 **Introduction**

41  
42  
43 Subclinical hypothyroidism (SCH) is characterized by a normal range of free thyroxin  
44  
45  
46 concentrations together with increased serum thyroxin (TSH) levels. Recently, SCH was  
47  
48  
49 found in 5% to 10% of the general population and 6% to 10% of women (approximately 15%  
50  
51  
52 was found in women more than 60 years old), while the incidence in males is 2.4 to 3% [1].  
53  
54

55  
56  
57 Although SCH is frequently asymptomatic, approximately 30% of patients have symptoms  
58

1  
2  
3  
4 indicative of thyroid hormone deficiency [2, 3]. However, the clinical significance and  
5  
6  
7  
8 therapeutic strategies of SCH are controversial .  
9

10  
11 C-IMT is a generally acknowledged measure of subclinical atherosclerotic alterations. It is  
12  
13  
14 increasingly used to evaluate vascular function in clinical analyses assessing the efficacy of  
15  
16  
17  
18 interventions that reduce atherosclerosis and related diseases [4]. This parameter is listed in  
19  
20  
21 the European guidelines for prophylaxis of cardiovascular disease, and 0.9 mm is the  
22  
23  
24 threshold value for C-IMT. Progression of atherosclerosis is indicated when the value of  
25  
26  
27  
28 C-IMT is over the threshold.  
29

30  
31 A meta-analysis involving 8 studies with 3602 participants found a relationship between  
32  
33  
34 SCH and C-IMT, especially when TSH > 10.0 mIU/l [5].L-T4 replacement should be used to  
35  
36  
37  
38 treat patients with clinical hypothyroidism; however, the treatment of SCH is complex.  
39

40  
41 Several placebo-controlled studies have shown the beneficial effects of L-T4 therapy on early  
42  
43  
44 atherosclerotic alterations and cardiovascular hazard in patients with SCH [6, 7]. Recently, in  
45  
46  
47  
48 a large-scale retrospective cohort study examining the efficacy of L-T4 replacement on  
49  
50  
51  
52 cardiovascular mortality, myocardial infarction and all-cause death, no beneficial effects in  
53  
54  
55  
56 patients with SCH were found, except for patients under 65 years old [8]. The purpose of the  
57  
58

1  
2  
3  
4 current study was to evaluate the effect of L-T4 therapy on endothelial function as evaluated  
5  
6  
7  
8 by C-IMT in patients with SCH.  
9

## 10 **Methods**

### 11 **Search strategy**

12  
13  
14  
15  
16  
17  
18  
19  
20 Studies published in English were found in the EMBASE, PUBMED, GOOGLE SCHOLAR  
21  
22  
23 and COCHRANE LIBRARY electronic databanks prior to June 2016. We identified studies  
24  
25  
26 that measured IMT in patients with SCH before and after treatment with L-T4. Studies were  
27  
28  
29  
30 obtained using three series of key items as subject headings: 1) hypothyroidism, thyroid  
31  
32  
33 disease, subclinical hypothyroid, subclinical thyroid dysfunction and thyroid-stimulating  
34  
35  
36 hormone; 2) intima media thickness, IMT, carotid wall thickness, C-IMT and carotid  
37  
38  
39 atherosclerosis; 3) levothyroxine, thyroxin, L-T4, replacement, therapy and treatment. For a  
40  
41  
42  
43 thorough review of the literature, we searched more studies by browsing the references of the  
44  
45  
46  
47 identified reports and review articles.  
48  
49  
50

### 51 **Criteria for study selection**



1  
2  
3  
4 Subjects with SCH have standard free thyroxin levels and increased TSH levels. There is  
5  
6  
7 still debate about the TSH reference interval; several reviews have proposed a TSH upper cut  
8  
9  
10 off between 4.5 and 5.0 mIU/l [9, 10], but some experts suggest that the peak TSH should be  
11  
12  
13 decreased to 2.5-3.0 mIU/l. Because there are no consistent conclusions, no specific TSH cut  
14  
15  
16 off was used to define SCH, but all articles had a cut off point from 3.6 to 5.5 mIU/l. To be  
17  
18  
19 included, a study had to satisfy the following conditions: 1) reported SCH defined based on a  
20  
21  
22 thyroid function test (normal free T4 and increased TSH); 2) defined as a RCT, which  
23  
24  
25 compared C-IMT in SCH patients in a L-T4 treatment and control group, or a self-controlled  
26  
27  
28 trial, which compared C-IMT value of a patient with SCH before and after L-T4 replacement.  
29  
30  
31  
32  
33

### 34 **Study selection**

35  
36  
37  
38  
39 Two investigators independently screened both abstracts and titles of the studies, and the  
40  
41  
42 studies were excluded when they did not conform to the inclusion criteria or they accorded  
43  
44  
45 with the exclusion criteria. Two investigators independently extracted data from the papers. If  
46  
47  
48 there was disagreement, a third reviewer was asked for advice. Discrepancies were solved by  
49  
50  
51  
52  
53 unanimous agreement.  
54  
55

### 56 **Data extraction**

57  
58  
59 7 / 30  
60

1  
2  
3  
4 The following information is contained in the data extraction table: 1) author 2) year of  
5  
6  
7  
8 publication 3) region 4) sample size 5) sample gender 6) mean age of the cohort 7) definition  
9  
10  
11 of SCH 8) duration of SCH 9) SCH detection method 10) mean L-T4 dosage 11) duration of  
12  
13  
14 treatment 12) thyroid function after treatment 13) IMT assessment 14) IMT values (mean  
15  
16  
17 with SD) before and after treatment with the corresponding treatment method.  
18  
19

### 20 21 22 **Assessment of study quality**

23  
24  
25  
26 The quality of non-randomized studies was evaluated using the MINORS method [11], which  
27  
28  
29 is based on the following items: a stated aim of the study, inclusion of consecutive patients,  
30  
31  
32 prospective collection of data, endpoint appropriate to the study aim, unbiased evaluation of  
33  
34  
35 endpoints, follow-up period appropriate to the major endpoint, and loss to follow-up not  
36  
37  
38 exceeding 5%.  
39  
40  
41  
42

43  
44 Methodological quality of the included RCTs was assessed using the Cochrane  
45  
46  
47 Handbook for Systematic Review of Interventions by several domains: generation of random  
48  
49  
50 sequence; allocation concealment; blinding; incomplete outcome data addressed; free of  
51  
52  
53 selective reporting; free of other bias.  
54  
55

### 56 57 **Statistical analysis**

58  
59 8 / 30  
60

1  
2  
3  
4 We represented the results as weighted mean differences (WMDs) with 95% confidence  
5  
6  
7 intervals (CIs) for continuous variables. For continuous outcomes, if all reports had  
8  
9  
10 uniform units of measurement (expressed as mm), we showed the WMD and 95% CIs as  
11  
12  
13 the results. We evaluated statistical heterogeneity across the studies by Cochrane's Q test  
14  
15  
16 ( $p < 0.1$  was statistically significant) and the  $I^2$  test ( $I^2 > 50\%$ : high heterogeneity;  $I^2 =$   
17  
18  
19  $25\%-50\%$ : moderate heterogeneity;  $I^2 < 25\%$ : low heterogeneity) [12]. The pooled effect  
20  
21  
22 size was assessed with a random-effect model when significant statistically heterogeneity  
23  
24  
25 was assessed with a random-effect model when significant statistically heterogeneity  
26  
27  
28 was present; in contrast, we also selected a fixed-effect model.  $p < 0.05$  was considered  
29  
30  
31 significant. The weighting of WMD in a fixed-effect model is inverse variance.  
32  
33  
34 However, the weighting of WMD in a random-effect model is I-V heterogeneity. We  
35  
36  
37 assessed publication bias with Begg's correlation test and Egger's regression method  
38  
39  
40 [13]. Sensitivity analysis was carried out for all papers in addition to the studies with  
41  
42  
43 boundary qualification. Pre-specified subgroup meta-analyses were performed to assess  
44  
45  
46 the between-study heterogeneity on the basis of the gender of participants (female or  
47  
48  
49 genders) and duration of treatment ( $>6$  months or  $\leq 6$  months). Among 9 including  
50  
51  
52 studies, 3 out of them are RCTs and the other of them are self-controlled trials. We  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 performed Statistical analysis of three RCTs. SCH treatment group of three RCTs also  
5  
6  
7 have the information on C-IMT values between pre-treatment and after-treatment in SCH  
8  
9  
10 patients. We combined the SCH treatment group of RCTs with the other self-controlled  
11  
12  
13 trials to performed Statistical analysis for fully revealing the effect of L-T4 treatment in  
14  
15  
16 SCH patients. Statistical analyses were performed with STATA 11 for Windows.  
17  
18  
19  
20  
21

## 22 **Results**

### 23 24 25 26 **Study selection**

27  
28  
29  
30 Three RCTs [7, 14, 15] (57 patients treated with L-T4 and 60 included in the control group)  
31  
32  
33 were selected for the meta-analysis, with a total of 117 patients. A total of 9 publications [7,  
34  
35  
36 14-21] with 247 SCH patients measured the C-IMT before and after L-T4. We selected these  
37  
38  
39  
40 studies among 107 potentially related articles (Fig. 1).  
41  
42  
43  
44

### 45 **Baseline characteristics and study quality**

46  
47  
48  
49 The baseline characteristics of the included trials are shown in Table 1(A)(B). The duration  
50  
51  
52 of therapy with L-T4 ranged from 2 to 18 months, the patient count varied from 14 to 56  
53  
54  
55 subjects, and the year of the publication was from 2004 to 2016. Six trials included female  
56  
57  
58

1  
2  
3  
4 and male patients, and the other three only examined female patients. Based on the type of  
5  
6  
7  
8 original research, the methodological evaluation of study quality was different. We used  
9  
10  
11 MINORS to assess the quality of the self-controlled trials. In general, the included self-controlled  
12  
13  
14 trials were of moderate quality (Table1) .The results of RCT quality are shown in Fig. 2.  
15  
16

### 17 18 **Progression of C-IMT in the follow-up and subgroup analysis**

19  
20  
21 A total of 3 RCTs involving 117 patients were analysed. L-T4 treatment significantly  
22  
23  
24 decreased C-IMT progression in SCH patients. (WMD, -0.05 mm, 95% CI -0.08, -0.01; p =  
25  
26  
27 0.025). The heterogeneity was very low ( $I^2=22.2\%$ ) (Fig. 3)  
28  
29

30  
31 The nine self-controlled experiments compared the value of C-IMT before replacement  
32  
33  
34 and after treatment. After L-T4 therapy, the thyroid function of all patients was normalized  
35  
36  
37  
38 from SCH, and then, patient IMT was measured again. Because clinical heterogeneity is  
39  
40  
41 relatively high. We selected random-effect model. L-T4 therapy was linked to a mild but  
42  
43  
44 significant decrease in the development of C-IMT (WMD, -0.04 mm, 95% CI -0.07, -0.02;  
45  
46  
47  
48 p = 0.050). The heterogeneity was moderate. ( $I^2=48.3\%$ ) (Fig. 4)  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Subgroup analyses stratified by gender revealed that L-T4 therapy caused a significant  
5  
6  
7 decrease in C-IMT among patients of mixed genders (WMD, -0.03 mm, 95% CI -0.06, -0.01;  
8  
9  
10  
11  $p = 0.145$ ). The outcomes showed moderate heterogeneity ( $I^2 = 39.2\%$ ). After L-T4 treatment,  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

TABLE 1(A). Summary of the Characteristics of the Included Studies

Author/ Year	Sample Size	Region	Gender	Mean Age (year)	Definition of SCH	SCH Duration (month)	L-T4 Dosage (initial value)	Treatment Duration (month)	Thyroid function after treatment	CIMT(mm) (Before/After)	Quality Score
Monzani 2004	23	Italy	Mixed genders	37±11	TSH >3.6 mIU/L	at least 6 months	25 -75 ug/d	10.5 <sup>a</sup>	normal	0.76±0.14 0.67±0.13	12
Soo-Kyung 2009	28	Korea	Mixed genders	36.0±6.2	TSH >5.5 mIU/L	newly diagnosed	67µg/d <sup>b</sup>	18 <sup>b</sup>	normal	0.67±0.11 0.60±0.10	9
Monica 2011	14	Brazil	female	43.4±9.8	TSH >4.0 mIU/L	–	44.23±18.13ug/d <sup>d</sup>	12	normal	0.66±0.11 0.66±0.15	10
Levent 2010	38	Turkey	Mixed genders	49.8±10.0	TSH >5.0 mIU/L	at least 2 months	101±27.46µg/d <sup>e</sup>	6 <sup>b</sup>	normal	0.64±0.13 0.63±0.12	11
Nasmi 2016	25	Iran	Mixed genders	35.9±7.6	TSH >4.0 mIU/L	–	50ug/d	2	normal	0.56±0.09 0.57±0.08	11
Ilknur 2014	56	Turkey	Mixed genders	41.3±14.5	TSH >4.2 mIU/L	–	25-50 u/d	–	normal	0.533±0.112 0.507±0.126	12
Dursun 2007	20	Turkey	female	36±11	TSH >4.2 mIU/L	newly diagnosed	25-100ug/d	5 <sup>b</sup>	normal	0.65±0.09 0.55±0.08	12
Adrees 2009	20	Ireland	female	50±9	–	at least 6 months	100 ± 30 ug/d <sup>c</sup>	18	normal	0.82±0.2 0.71±0.2	10
Dilek 2015	23	Turkey	Mixed genders	35.2±10.7	TSH >4.0 mIU/L	at least 6 months	–	6	normal	0.51±0.09 0.46±0.07	11

1  
2  
3  
4  
5  
6  
7 Abbreviations: TSH, thyroid-stimulating hormone; CIMT, Carotid intima-media thickness; L-T4, levothyroxine.

8  
9 Mixed genders=including male and female. Age and IMT are expressed as mean± s.d.

10  
11 <sup>a</sup> median ; <sup>b</sup> mean; <sup>c</sup> mean± s.d; <sup>d</sup> median± interquartile range  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49



TABLE 1(B). Summary of the Characteristics of the Included Studies

Author	TSH assay	Carotid IMT assessment
Monzani	ultrasensitive immunoradiometric assay	both the near and far wall of the right and left common carotid artery and carotid bifurcation(high-resolution ultrasonography)
Soo-Kyung	chemiluminescent immunometric assay	20 mm proximal to the origin of the carotid bulb (high-resolution ultrasonographic system)
Monica	immunochemiluminescence	both the near and far wall of the right and left common artery and the carotid bifurcation.(high-resolution ultrasound imaging)
Levent	Chemiluminescence immunometric assay	approximately 1-cm segment from both the left and right CCA proximal and distal portions (Ultrasonographic images)
Nasmi	–	sonogram B-mode images
Ilknur	electrochemiluminescence immunoassays	Three arterial wall segments of the common carotid artery were measured bilaterally after imaging from a fixed lateral transducer angle and designated (high-resolution B-mode ultrasonography)
Dursun	immunoassay	right and left extracranial carotid arteries: the CCA (1 cm proximal to the dilation of the carotid bulb), the bifurcation (the 1-cm segment proximal to the flow divider), and the internal carotid artery (the 1-cm segment in the internal branch distal to the flow divider).(high-resolution ultrasonography )
Adrees	chemiluminescent immunometric assay	1 cm proximal to the carotid bulb when a satisfactory position was found.(calibrated ultrasound machine)
Dilek	–	ultrasound system

Abbreviations: CCA, common carotid artery.

1  
2  
3  
4 female participants with SCH displayed a significant reduction in C-IMT (WMD, -0.07 mm,  
5  
6  
7 95% CI -0.14, -0.01;  $p = 0.186$ ). The heterogeneity was moderate ( $I^2 = 40.5\%$ ) (Fig.5).  
8  
9

10 Subgroup analyses were performed using the duration of L-T4 replacement. Except for one reports,  
11  
12  
13  
14 all trials had information on the length of the therapy. There was a significant decrease in C-IMT in  
15  
16  
17 the patients with long-term (>6 months) treatment (WMD, -0.05 mm, 95% CI -0.08, -0.02;  $p=0.335$ ).  
18  
19  
20 The outcome showed low heterogeneity ( $I^2 = 12.3\%$ ). A non-significant reduction was found in  
21  
22  
23 C-IMT in the participants with short-term ( $\leq 6$  months) replacement therapy (WMD, -0.04 mm, 95%  
24  
25  
26 CI -0.08, 0.01;  $p=0.015$ ). The heterogeneity was high ( $I^2 = 71.3\%$ ). (Fig. 6).  
27  
28  
29

### 30 **Changes in metabolic parameters**

31  
32  
33 Table 2 indicates the changes in metabolic parameters from pre-replacement to  
34  
35  
36  
37 post-treatment. L-T4 therapy was linked to significant reductions in TC, TG, LDL, SBP,  
38  
39  
40 DBP, and LP(a) and decreased FMD. There were no significant changes in BMI, waist  
41  
42  
43 circumference, HDL, ApoA, ApoB and glucose between the pre-treatment and post-therapy  
44  
45  
46  
47 conditions.  
48  
49

### 50 **Sensitivity and publication bias evaluation**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

We carried out sensitivity analyses by sequentially eliminating one study to probe the change in the total WMD and 95% CI of C-IMT. The results of three RCT sensitivity

For peer review only

**Table 2**

The difference of the changes in metabolic parameters between pre-treatment and post-treatment.

Parameters	No. of patients	WMD (95% CI)	P-value
Waist circumference (cm)	66	-0.544(-4.041,2.954)	0.761
BMI (kg/m <sup>2</sup> )	152	-0.231(-1.044,0.582)	0.577
Glucose (mmol/L)	48	0.090(-0.109,0.289)	0.375
SBP (mmHg)	109	-9.391(-14.405,-4.377)	<0.001
DBP (mmHg)	109	-5.693(-8.471,-2.916)	<0.001
TC (mg/dl)	166	-9.037(-16.635,-1.439)	0.02
TG (mg/dl)	166	-9.842(-18.763,-0.921)	0.031
HDL (mg/dl)	166	-1.032(-4.059,1.995)	0.504
LDL (mg/dl)	166	-14.303(-19.133,-9.472)	<0.001
FMD (%)	39	3.962(2.636,5.289)	<0.001
ApoA (mg/dl)	37	-10.092(-23.173,2.989)	0.131
ApoB (mg/dl)	37	-7.718(-21.723,6.287)	0.28
LP(a) (mg/l)	34	-9.974(-12.844,-7.103)	<0.001

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA, Apolipoprotein A; ApoB, Apolipoprotein B; Lp(a), lipoprotein(a); WMD, weighted mean difference; CI: confidence interval; FMD, flow-mediated dilatation.

indicated no variation in the direction of WMD when each publication was removed.

(Fig.s1) . Neither Egger's test (p=0.881) nor Begg's test (p=0.602) of C-IMT in SCH

1  
2  
3  
4 manifested publication biases. ( Fig.s2) ( Fig.s3). We also evaluate the sensitivity and  
5  
6  
7  
8 publication bias of the nine self-controlled trial. The results showed that there was only a  
9  
10  
11 slight change in the WMD or 95% CI, and no change in the direction of WMD when any one  
12  
13  
14 study was omitted. ( Fig.s4) Egger's test ( $p=0.458$ ) and Begg's test ( $p=0.602$ ) of C-IMT in  
15  
16  
17  
18 SCH manifested publication biases. ( Fig.s5) ( Fig.s6) .  
19

## 20 21 **Discussion**

22  
23  
24 This meta-analysis indicated that L-T4 has beneficial effects on the development of  
25  
26  
27  
28 C-IMT. Decreased C-IMT was also observed with longer treatment (>6 months). L-T4  
29  
30  
31 therapy of SCH participants also resulted in a significant reduction in TC, TG, LDL, SBP,  
32  
33  
34  
35 DBP, LP(a), and FMD.  
36  
37

38 The American Heart Association/American College of Cardiology guidelines designated  
39  
40  
41 C-IMT along with coronary artery calcium (CAC) score as a class IIa recommendation for  
42  
43  
44  
45 cardiovascular risk assessment in asymptomatic adults at intermediate risk of cardiovascular  
46  
47  
48 disease. For a 0.1 mm difference in C-IMT, the prospective risk of myocardial infarction  
49  
50  
51  
52 increased from 10% to 15%, and the stroke risk was increased from 13% to 18% [5]. The  
53  
54  
55  
56 result showed that C-IMT in SCH patients can be reversed by L-T4 replacement. The  
57  
58

1  
2  
3  
4 mechanism underlying the L-T4-mediated decrease in C-IMT has not been fully elucidated.  
5  
6

7 TSHR, hyperlipidaemia and blood pressure may contribute to this result.  
8  
9

10  
11 In SCH, the increased TSH is the only prominent change, and increased TSH can bind  
12  
13 with the TSH receptor (TSHR) to perform its function. Balzan et al. [22] revealed that  
14  
15 micro-vascular endothelial cells produce TSHR, which may help to elucidate this relationship.  
16  
17 Recently, Tian et al. [23] published a study to identify the potential function of the TSHR and  
18  
19 showed that increased TSH aggravated endothelial dysfunction. However, L-T4 can control  
20  
21 the elevated TSH by reversing above-mentioned changes to reduce the mean C-IMT.  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 Six out of 13 papers in a systemic review reported that L-T4 treatment improved TC  
32  
33 and LDL [24]. A RCT trial with the same conclusion further supported this hypothesis  
34  
35 [8]. Among four markers of hyperlipidaemia (TC, TG, LDL, HDL), we observed  
36  
37 non-significant differences only in HDL between pre-treatment and post-replacement  
38  
39 conditions, which is supported by previous study with similar findings [25]. Reports by  
40  
41 Kannel et al. [26] and Lewington et al. [27] showed that the TC/HDL ratio is more important  
42  
43 in the progress of coronary heart disease than either TC or HDL alone. Although HDL  
44  
45 concentration was not changed after restoration of euthyroidism by L-T4 replacement in SCH  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 patients in our study, L-T4 treatment altered the TC/HDL ratio. . Hyperlipidaemia promotes  
5  
6  
7  
8 endothelial dysfunction because it can inhibit the NO synthesis pathway in endothelial cells  
9  
10  
11 [28]. Meanwhile, a recent paper found that SCH can cause endothelial dysfunction because of  
12  
13  
14 a decrease in NO availability, which is partly independent of dyslipidaemia, and L-T4  
15  
16  
17 supplementation can reverse endothelial dysfunction [29]. Thus, we found that SCH not only  
18  
19  
20 results in endothelial dysfunction but is also an independent risk factor of dyslipidaemia; then,  
21  
22  
23  
24 dyslipidaemia further amplifies endothelial dysfunction. L-T4 treatment of SCH patients can  
25  
26  
27  
28 reduce these effects.  
29

30  
31 A meta-analysis showed that blood pressure was an independent risk factor for C-IMT  
32  
33  
34 [30]. Recently, an another meta-analysis demonstrated that SCH is linked to higher SBP and  
35  
36  
37  
38 DBP levels [31]. We know little about the mechanism of SCH-associated hypertension;  
39  
40  
41 nevertheless, hypothyroidism increases vascular resistance, enhances blood pressure, salt  
42  
43  
44  
45 sensitivity and abnormal sodium metabolism, which may promote the development of  
46  
47  
48 hypertension.  
49

50  
51  
52 For the subgroup of short duration ( $\leq 6$  months), an insignificant difference of C-IMT was  
53  
54  
55  
56 observed after treatment. Meanwhile, mean C-IMT in SCH subjects undergoing long-term  
57  
58

1  
2  
3  
4 treatment significantly increased compared to that in the pre-treatment condition. This  
5  
6  
7  
8 phenomenon was confirmed in our clinical observation. The major reason is that the duration  
9  
10  
11 of treatment is too short to improve C-IMT. The rate of progression of IMT in the common  
12  
13  
14 carotid artery was approximately 0.01 mm/year.  
15  
16

17  
18 For stratification by gender, we find a significant difference in female patients between  
19  
20  
21 pre-replacement and post-replacement. Meanwhile, for the mixed genders subgroup, mean  
22  
23  
24 C-IMT was significantly reduced after treatment. Although the prevalence of SCH is a little  
25  
26  
27 difference between women and general population, the effects of levothyroxine (L-T4) on  
28  
29  
30 C-IMT are similar. This suggests that the changes of C-IMT are similar when we control  
31  
32  
33 thyroid function in the normal range regardless of gender.  
34  
35  
36

### 37 ***Limitations***

38  
39 The number of including studies was small, and the overall population of these trials  
40  
41  
42 was not large. Meta analysis has moderate heterogeneity. Difficult assessment of the  
43  
44  
45 potential publication bias mainly due to the previous two factors. Additionally, we did  
46  
47  
48 not perform subgroup analysis according to the level of TSH (the cutoff value is 10  
49  
50  
51 mU/ml to distinguish mild SCH and severe SCH) because the original studies did not  
52  
53  
54 perform analyses according to the level of TSH. Finally, we did not perform subgroup  
55  
56  
57  
58



1  
2  
3  
4 analysis by mean age (>65 or <65 years) because all participants' mean age was below  
5  
6  
7 65 years.  
8  
9

## 10 **Conclusion**

11  
12  
13  
14 Our study suggests that C-IMT in SCH patients can be reversed by L-T4 replacement.  
15  
16  
17  
18 Hyperlipidaemia and hypertension may improve after L-T4 therapy. Long L-T4 replacement  
19  
20  
21 duration (>6 months) is more useful compared to short-term duration for improving C-IMT  
22  
23  
24 in SCH patients. Therefore, L-T4 supplementation can prevent or inhibit the progression of  
25  
26  
27 atherosclerosis, at least in SCH patients. RCTs with more sample size are needed to confirm  
28  
29  
30 these findings.  
31  
32

## 33 contributorship statement

34  
35  
36  
37  
38 Zhao Tong and Chen Baomin made search strategies, searched papers from  
39  
40  
41 databases, assessed of study quality ,independently extracted data from the papers  
42  
43  
44 and wrote the paper Wang Haoyu as a third reviewer was asked for advice,If there was  
45  
46  
47 disagreement.Zhou Yingying, Wang Xinyi and Zhang Yuanyuan Participated in the  
48  
49  
50 revision of the paper. Shan Zhongyan provided some advices on the discussion section  
51  
52  
53 of this article.  
54  
55  
56  
57  
58

### competing interests statement

The author denies that he has any intention to obtain any financial interests.

### Funding

There are no funders to report for this submission

### Data Sharing Statement

No additional unpublished data are available

## References

1. Cooper DS. Clinical practice. Subclinical hypothyroidism. *N Engl J Med*. 2001;345(4):260-5. Epub 2001/07/28. doi: 10.1056/nejm200107263450406. PubMed PMID: 11474665.
2. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. *Annals of internal medicine*. 1984;101(1):18-24. Epub 1984/07/01. PubMed PMID: 6428290.
3. Monzani F, Caraccio N, Del Guerra P, Casolaro A, Ferrannini E. Neuromuscular symptoms and dysfunction in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy. *Clin Endocrinol (Oxf)*. 1999;51(2):237-42. Epub 1999/09/01. PubMed PMID: 10468996.
4. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. *The American journal of cardiology*. 2002;90(10c):18I-21I. Epub 2002/12/03. PubMed PMID: 12459422.
5. Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH. Carotid intima-media thickness in patients with subclinical hypothyroidism: a meta-analysis. *Atherosclerosis*. 2013;227(1):18-25. Epub 2012/11/20. doi:

1  
2  
3 10.1016/j.atherosclerosis.2012.10.070. PubMed PMID: 23159101.  
4

5 6. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on  
6 cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized,  
7 crossover trial. *The Journal of clinical endocrinology and metabolism*. 2007;92(5):1715-23. Epub 2007/02/15.  
8 doi: 10.1210/jc.2006-1869. PubMed PMID: 17299073.  
9

10 7. Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Viridis A, et al. Effect of levothyroxine  
11 replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-  
12 controlled study. *The Journal of clinical endocrinology and metabolism*. 2004;89(5):2099-106. Epub  
13 2004/05/06. doi: 10.1210/jc.2003-031669. PubMed PMID: 15126526.  
14

15 8. Andersen MN, Olsen AM, Madsen JC, Faber J, Torp-Pedersen C, Gislason GH, et al. Levothyroxine  
16 Substitution in Patients with Subclinical Hypothyroidism and the Risk of Myocardial Infarction and Mortality.  
17 *PLoS One*. 2015;10(6):e0129793. Epub 2015/06/13. doi: 10.1371/journal.pone.0129793. PubMed PMID:  
18 26069971; PubMed Central PMCID: PMC4466400.  
19

20 9. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the  
21 evidence for the U.S. Preventive Services Task Force. *Annals of internal medicine*. 2004;140(2):128-41. Epub  
22 2004/01/22. PubMed PMID: 14734337.  
23

24 10. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific  
25 review and guidelines for diagnosis and management. *Jama*. 2004;291(2):228-38. Epub 2004/01/15. doi:  
26 10.1001/jama.291.2.228. PubMed PMID: 14722150.  
27

28 11. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized  
29 studies (minors): development and validation of a new instrument. *ANZ journal of surgery*. 2003;73(9):712-6.  
30 Epub 2003/09/06. PubMed PMID: 12956787.  
31

32 12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ (Clinical  
33 research ed)*. 2003;327(7414):557-60. Epub 2003/09/06. doi: 10.1136/bmj.327.7414.557. PubMed PMID:  
34 12958120; PubMed Central PMCID: PMC192859.  
35

36 13. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with  
37 publication and other biases in meta-analysis. *BMJ (Clinical research ed)*. 2001;323(7304):101-5. Epub  
38 2001/07/14. PubMed PMID: 11451790; PubMed Central PMCID: PMC1120714.  
39

40 14. Cabral MD, Teixeira P, Soares D, Leite S, Salles E, Waisman M. Effects of thyroxine replacement on  
41 endothelial function and carotid artery intima-media thickness in female patients with mild subclinical  
42 hypothyroidism. *Clinics (Sao Paulo)*. 2011;66(8):1321-8. doi: 10.1590/S1807-59322011000800003. PubMed  
43 PMID: 21915478; PubMed Central PMCID: PMC3161206.  
44

45 15. Duman D, Demirtunc R, Sahin S, Esertas K. The effects of simvastatin and levothyroxine on intima-media  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
25 / 30

1  
2  
3 thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective,  
4 randomized-controlled study. *J Cardiovasc Med (Hagerstown)*. 2007;8(12):1007-11. doi:  
5 10.2459/JCM.0b013e3282f03bc1. PubMed PMID: 18163011.  
6  
7

8 16. Unsal IO, Topaloglu O, Cakir E, Bozkurt NC, Karbek B, Gungunes A, et al. Effect of L-thyroxin therapy on  
9 thyroid volume and carotid artery intima-media thickness in the patients with subclinical hypothyroidism. *J*  
10 *Med Disord*. 2014;2(1):1. doi: 10.7243/2053-3659-2-1.  
11  
12

13 17. Kebapcilar L, Comlekci A, Tuncel P, Solak A, Secil M, Gencil O, et al. Effect of levothyroxine replacement  
14 therapy on paraoxonase-1 and carotid intima-media thickness in subclinical hypothyroidism. *Med Sci Monit*.  
15 2010;16(1):CR41-7. PubMed PMID: 20037493.  
16  
17

18 18. Adrees M, Gibney J, El-Saeity N, Boran G. Effects of 18 months of L-T4 replacement in women with  
19 subclinical hypothyroidism. *Clinical endocrinology*. 2009;71(2):298-303. doi:  
20 10.1111/j.1365-2265.2008.03509.x.  
21  
22

23 19. Yazıcı D, Özben B, Toprak A, Yavuz D, Aydın H, Tarçın Ö, et al. Effects of restoration of the euthyroid state  
24 on epicardial adipose tissue and carotid intima media thickness in subclinical hypothyroid patients. *Endocrine*.  
25 2014;48(3):909-15. doi: 10.1007/s12020-014-0372-1.  
26  
27

28 20. Niknam N, Khalili N, Khosravi E, Nourbakhsh M. Endothelial dysfunction in patients with subclinical  
29 hypothyroidism and the effects of treatment with levothyroxine. *Advanced biomedical research*. 2016;5:38.  
30 Epub 2016/04/22. doi: 10.4103/2277-9175.178783. PubMed PMID: 27099851; PubMed Central PMCID:  
31 PMCPmc4815523.  
32  
33

34 21. Kim SK, Kim SH, Park KS, Park SW, Cho YW. Regression of the increased common carotid artery-intima  
35 media thickness in subclinical hypothyroidism after thyroid hormone replacement. *Endocr J*. 2009;56(6):753-8.  
36 Epub 2009/06/10. PubMed PMID: 19506325.  
37  
38

39 22. Balzan S, Del Carratore R, Nicolini G, Befly P, Lubrano V, Forini F, et al. Proangiogenic effect of TSH in  
40 human microvascular endothelial cells through its membrane receptor. *The Journal of clinical endocrinology*  
41 *and metabolism*. 2012;97(5):1763-70. Epub 2012/03/16. doi: 10.1210/jc.2011-2146. PubMed PMID: 22419707.  
42  
43

44 23. Tian L, Zhang L, Liu J, Guo T, Gao C, Ni J. Effects of TSH on the function of human umbilical vein endothelial  
45 cells. *Journal of molecular endocrinology*. 2014;52(2):215-22. Epub 2014/01/22. doi: 10.1530/jme-13-0119.  
46  
47  
48 PubMed PMID: 24444496.  
49

50 24. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on  
51 serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. *The Journal of*  
52 *clinical endocrinology and metabolism*. 2000;85(9):2993-3001. Epub 2000/09/22. doi: 10.1210/jcem.85.9.6841.  
53  
54  
55 PubMed PMID: 10999775.  
56

57 25. Asranna A, Taneja RS, Kulshreshta B. Dyslipidemia in subclinical hypothyroidism and the effect of  
58  
59  
60

- 1  
2  
3 thyroxine on lipid profile. *Indian J Endocrinol Metab.* 2012;16(Suppl 2):S347-9. Epub 2013/04/09. doi:  
4 10.4103/2230-8210.104086. PubMed PMID: 23565423; PubMed Central PMCID: PMC3603071.
- 5  
6  
7 26. Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ. Usefulness of the triglyceride-high-density  
8 lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and  
9 cardiometabolic risk (from the Framingham Offspring Cohort). *The American journal of cardiology.*  
10 2008;101(4):497-501. Epub 2008/03/04. doi: 10.1016/j.amjcard.2007.09.109. PubMed PMID: 18312765;  
11 PubMed Central PMCID: PMC3753679.
- 12  
13  
14 27. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular  
15 mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with  
16 55,000 vascular deaths. *Lancet.* 2007;370(9602):1829-39. Epub 2007/12/07. doi:  
17 10.1016/s0140-6736(07)61778-4. PubMed PMID: 18061058.
- 18  
19  
20 28. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction:  
21 dysregulation of dimethylarginine dimethylaminohydrolase. *Circulation.* 1999;99(24):3092-5. Epub 1999/06/22.  
22 PubMed PMID: 10377069.
- 23  
24  
25 29. Taddei S, Caraccio N, Viridis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired endothelium-dependent  
26 vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. *The Journal of clinical  
27 endocrinology and metabolism.* 2003;88(8):3731-7. Epub 2003/08/14. doi: 10.1210/jc.2003-030039. PubMed  
28 PMID: 12915662.
- 29  
30  
31 30. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, et al. Carotid intima-media thickness and  
32 antihypertensive treatment: a meta-analysis of randomized controlled trials. *Stroke; a journal of cerebral  
33 circulation.* 2006;37(7):1933-40. Epub 2006/06/10. doi: 10.1161/01.str.0000227223.90239.13. PubMed PMID:  
34 16763185.
- 35  
36  
37 31. Cai Y, Ren Y, Shi J. Blood pressure levels in patients with subclinical thyroid dysfunction: a meta-analysis of  
38 cross-sectional data. *Hypertension research : official journal of the Japanese Society of Hypertension.*  
39 2011;34(10):1098-105. Epub 2011/07/29. doi: 10.1038/hr.2011.91. PubMed PMID: 21796125.
- 40  
41  
42  
43  
44  
45  
46  
47

48 Fig.1. Process of study selection.

49

50

51

52 Abbreviations: IMT: intima-media thickness; SCH: subclinical hypothyroidism

53

54

55 Fig.2. Quality assessment of the included studies.

56

57

58

59

60

1  
2  
3  
4 Fig.3. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals for improvement  
5  
6  
7  
8 in carotid intima-media thickness comparing L-T4 treatment to the control in a fixed effects model.  
9

10  
11 Legend for x-axis: Negative values equals improvement in IMT.  
12  
13

14  
15  
16  
17  
18 Fig.4. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals compared the  
19  
20  
21 value of C-IMT before replacement and after treatment in a random-effect model.  
22  
23

24  
25 Legend for x-axis: Negative values equals improvement in IMT.  
26  
27  
28  
29  
30

31 Fig.5.Subgroup analyses of carotid intima-media thickness changes based on gender in a random effects model.  
32  
33

34  
35 Legend for x-axis: Negative values equals improvement in IMT.  
36  
37  
38  
39  
40

41 Fig.6.Subgroup analyses of carotid intima-media thickness changes based on duration of L-T4 replacement in a  
42  
43  
44  
45 random effects model.  
46

47  
48 Legend for x-axis: Negative values equals improvement in IMT.  
49  
50

51  
52 Long study duration= duration of L-T4 replacement >6 months  
53

54  
55 Short study duration= duration of L-T4 replacement ≤6 months  
56  
57  
58

1  
2  
3  
4  
5  
6  
7  
8 Fig.S1 Begg's funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in  
9  
10  
11 RCT studies.

12  
13  
14  
15  
16  
17  
18 Fig.S2 Begg's funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in  
19  
20  
21 self-controlled studies.

22  
23  
24  
25  
26  
27  
28 Fig.S3 Funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in RCT  
29  
30  
31 studies .

32  
33  
34  
35  
36  
37  
38 Fig.S4 Funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in  
39  
40  
41 self-controlled studies.

42  
43  
44  
45  
46  
47  
48 Fig.S5 Sensitivity analysis of the RCT studies included in the meta-analysis. The figure shows the WMD  
49  
50  
51  
52 obtained by combined analysis of the remaining studies after the successive exclusion of each study individually.

53  
54  
55 The excluded study is listed on the left, and the corresponding horizontal lines indicate the WMD and CI

1  
2  
3  
4 obtained by re-calculation after its exclusion. The CI for the overall meta-analysis of the studies is indicated by  
5  
6  
7 two vertical lines.  
8  
9

10  
11  
12  
13  
14 Fig.S6 Sensitivity analysis of the self-controlled studies included in the meta-analysis. The figure shows the  
15  
16  
17 WMD obtained by combined analysis of the remaining studies after the successive exclusion of each study  
18  
19  
20 individually. The excluded study is listed on the left, and the corresponding horizontal lines indicate the WMD  
21  
22  
23 and CI obtained by re-calculation after its exclusion. The CI for the overall meta-analysis of the studies is  
24  
25  
26  
27 indicated by two vertical lines.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Fig.1. Process of study selection.

Abbreviations: IMT: intima-media thickness; SCH: subclinical hypothyroidism

123x167mm (300 x 300 DPI)




Fig.2. Quality assessment of the included studies.

402x131mm (300 x 300 DPI)

peer review only




Fig.3. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals for improvement in carotid intima-media thickness comparing L-T4 treatment to the control in a fixed effects model.

Legend for x-axis: Negative values equals improvement in IMT

345x221mm (300 x 300 DPI)

View only




Fig.4. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals compared the value of C-IMT before replacement and after treatment in a random-effect model. Legend for x-axis: Negative values equals improvement in IMT.

309x221mm (300 x 300 DPI)




Fig.5.Subgroup analyses of carotid intima-media thickness changes based on gender in a random effects model.

Legend for x-axis: Negative values equals improvement in IMT.

288x221mm (300 x 300 DPI)




Fig.6.Subgroup analyses of carotid intima-media thickness changes based on duration of L-T4 replacement in a random effects model.

Legend for x-axis: Negative values equals improvement in IMT.  
 Long study duration= duration of L-T4 replacement >6 months  
 Short study duration= duration of L-T4 replacement ≤6 months

283x221mm (300 x 300 DPI)


only

Meta-analysis estimates, given named study is omitted


| Lower CI Limit

○ Estimate

| Upper CI Limit




# Begg's funnel plot with pseudo 95% confidence limits



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>




# Funnel plot with pseudo 95% confidence limits




# Meta-analysis estimates, given named study is omitted


| Lower CI Limit      ○ Estimate      | Upper CI Limit



# Begg's funnel plot with pseudo 95% confidence limits



# Funnel plot with pseudo 95% confidence limits



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56



# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5-6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8-9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ for each meta-analysis).	9



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8-9
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	11
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	17
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	15
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	18
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	18
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	18
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19-20
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	3
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	25
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	25

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: A meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-016053.R2
Article Type:	Research
Date Submitted by the Author:	30-Aug-2017
Complete List of Authors:	Zhao, Tong; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Chen, Baomin; First Affiliated Hospital, Chinese Medical University, liver and gall surgical Zhou, Yingying; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Wang, Xinyi; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Zhang, Yuanyuan; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Wang, Haoyu; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism Shan, Zhongyan; First Affiliated Hospital, Chinese Medical University, Endocrinology and Metabolism
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Nutrition and metabolism, Cardiovascular medicine
Keywords:	subclinical hypothyroidism, carotid intima-media thickness, thyroxin, cardiovascular risk

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Effect of levothyroxine on the progression of carotid intima-media**  
5  
6  
7 **thickness in subclinical hypothyroidism patients: A meta-analysis**  
8  
9

10  
11 Zhao Tong, Chen Baomin, Zhou Yingying, Wang xinyi, Zhang yuanyuan, Wang haoyu, Shan

12  
13  
14  
15 Zhongyan

16  
17  
18  
19  
20 *Department of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning*

21  
22  
23 *Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China*

24  
25  
26  
27 *Medical University, No.155 Nanjing North Street, Shenyang 110001, China*

28  
29  
30 the email address of the corresponding author

31  
32  
33 Zhao, Tong *cmu\_zhaotong@163.com*

34  
35  
36 Chen, Baomin *cbm19910330@163.com*

37  
38  
39 Zhou, Yingying *18937856536@163.com*

40  
41  
42 Wang, Xinyi *wangxinyi4125@163.com*

43  
44  
45 Zhang, Yuanyuan [yuan-anpo@163.com](mailto:yuan-anpo@163.com)

46  
47  
48 Wang, Haoyu [why\\_endocrinology@foxmail.com](mailto:why_endocrinology@foxmail.com)

49  
50  
51  
52 Shan, Zhongyan (Corresponding Author) *shanzhongyan@medmail.com.cn*

53  
54  
55  
56  
57 **Abstract**

58  
59 1 / 30  
60



1  
2  
3  
4 **Background and aims:** Subclinical hypothyroidism (SCH) has been associated with  
5  
6  
7 increased carotid intima-media thickness (C-IMT) in recent studies, but the effects of  
8  
9  
10 levothyroxine (L-T4) on C-IMT in SCH patients are still controversial. The aim of the current  
11  
12  
13 study was to evaluate the effect of L-T4 therapy on endothelial function as determined by  
14  
15  
16  
17 C-IMT in patients with SCH.  
18  
19

20  
21 **Methods:** Prior to July 2016, we searched the PUBMED, EMBASE, COCHRANE  
22  
23  
24 LIBRARY and GOOGLE SCHOLAR databases we selected published randomized  
25  
26  
27 controlled trials (RCTs) and self-controlled trials.  
28  
29

30  
31 **Results:** Three RCTs with 117 patients were considered appropriate for the meta-analysis.  
32  
33  
34 The results of the meta-analysis indicated that L-T4 significantly decreased the development  
35  
36  
37 of C-IMT [weighted mean difference (WMD), -0.05 mm, 95% CI -0.08, -0.01; p = 0.025].  
38  
39  
40 We also analysed 9 studies (self-controlled trials) with 247 patients and extracted the IMT of  
41  
42  
43 SCH patients before and after L-T4 treatment. After L-T4 therapy, the pooled estimate of the  
44  
45  
46 WMD of decreased C-IMT was -0.04 mm (95% CI -0.07, -0.02; p = 0.05). Subgroup  
47  
48  
49 analysis showed that L-T4 therapy was associated with a decrease in C-IMT among patients  
50  
51  
52 of mixed genders (WMD, -0.03 mm, 95% CI -0.06, -0.01; p = 0.145). L-T4 therapy was  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 associated with a decrease in C-IMT among female patients (WMD, -0.07 mm, 95% CI -0.14,  
5  
6  
7 -0.01;  $p = 0.186$ ). Longer treatment (>6 months) also resulted in a significant decrease in  
8  
9  
10  
11 C-IMT (WMD, -0.05 mm, 95% CI -0.08, -0.02;  $p=0.335$ ).  
12  
13

14 **Conclusion:** This meta-analysis indicates that L-T4 treatment of SCH patients can reduce  
15  
16  
17 C-IMT, possibly as a result of the reduction of TC, TG, LDL-C, SBP, DBP, LP(a), and FMD.  
18  
19  
20  
21 Decreased C-IMT was observed in SCH patients after long-term (>6 months) L-T4 treatment.  
22  
23  
24  
25 RCTs with large samples are needed to verify these observations.  
26  
27

28 ***Strengths and limitations of this study:***  
29

30 ***Strengths***  
31  
32

33 1. A strong quality evidence on the effect of L-T4 therapy in SCH patients is preformed.  
34  
35  
36 Methodology, according to the different types of original literature, we used different  
37  
38  
39 method of statistical analysis and study quality evaluation. According to different  
40  
41  
42 heterogeneity, we adopt different effect model. This embodies the rigor of methodology  
43  
44  
45  
46  
47 2. We analysis other metabolic parameters to better explain to effect of L-T4 therapy in  
48  
49  
50  
51 SCH.  
52  
53

54 ***Limitations***  
55  
56  
57  
58

1  
2  
3  
4 1. The number of including studies was small, and the overall population of these trials was  
5  
6  
7  
8 not large. Meta analysis has moderate heterogeneity. Difficult assessment of the potential  
9  
10  
11 publication bias mainly due to the previous two factors.

12  
13  
14  
15 2. We did not perform subgroup analysis according to the level of TSH (the cutoff value is 10  
16  
17  
18 mU/ml to distinguish mild SCH and severe SCH) because the original studies did not  
19  
20  
21  
22 perform analyses according to the level of TSH.

23  
24  
25  
26 3. We did not perform subgroup analysis by mean age (>65 or <65 years) because all  
27  
28  
29  
30 participants' mean age was below 65 years.

31  
32  
33  
34 **Keywords:** subclinical hypothyroidism; carotid intima-media thickness; thyroxin;  
35  
36  
37  
38 cardiovascular risk

## 39 40 41 42 **Introduction**

43  
44  
45 Subclinical hypothyroidism (SCH) is characterized by a normal range of free thyroxin  
46  
47  
48 concentrations together with increased serum thyroxin (TSH) levels. Recently, SCH was  
49  
50  
51  
52 found in 5% to 10% of the general population and 6% to 10% of women (approximately 15%  
53  
54  
55  
56 was found in women more than 60 years old), while the incidence in males is 2.4 to 3% [1].

1  
2  
3  
4 Although SCH is frequently asymptomatic, approximately 30% of patients have symptoms  
5  
6  
7 indicative of thyroid hormone deficiency [2, 3]. However, the clinical significance and  
8  
9  
10 therapeutic strategies of SCH are controversial .  
11  
12

13  
14 C-IMT is a generally acknowledged measure of subclinical atherosclerotic alterations. It is  
15  
16  
17 increasingly used to evaluate vascular function in clinical analyses to assess the efficacy of  
18  
19  
20 interventions that reduce atherosclerosis and related diseases [4]. This parameter is listed in  
21  
22  
23 the European guidelines for prophylaxis of cardiovascular disease, and 0.9 mm is the  
24  
25  
26 threshold value for C-IMT. Progression of atherosclerosis is indicated when the value of  
27  
28  
29 C-IMT is over the threshold.  
30  
31  
32

33  
34 A meta-analysis involving 8 studies with 3602 participants found a relationship between  
35  
36  
37 SCH and C-IMT, especially when TSH > 10.0 mIU/l [5]. L-T4 replacement should be used to  
38  
39  
40 treat patients with clinical hypothyroidism; however, the treatment of SCH is complex.  
41  
42  
43

44  
45 Several placebo-controlled studies have shown the beneficial effects of L-T4 therapy on early  
46  
47  
48 atherosclerotic alterations and cardiovascular hazard in patients with SCH [6, 7]. Recently, in  
49  
50  
51 a large-scale retrospective cohort study examining the efficacy of L-T4 replacement on  
52  
53  
54 cardiovascular mortality, myocardial infarction and all-cause death, no beneficial effects in  
55  
56  
57

1  
2  
3  
4 patients with SCH were found, except for patients under 65 years old [8]. The purpose of the  
5  
6  
7  
8 current study was to evaluate the effect of L-T4 therapy on endothelial function as evaluated  
9  
10  
11 by C-IMT in patients with SCH.  
12

## 13 14 **Methods**

### 15 16 17 18 **Search strategy**

19  
20  
21  
22  
23 Studies published in English were found in the EMBASE, PUBMED, GOOGLE SCHOLAR  
24  
25  
26 and COCHRANE LIBRARY electronic databanks prior to June 2016. We identified studies  
27  
28  
29 that measured IMT in patients with SCH before and after treatment with L-T4. Studies were  
30  
31  
32 identified and evaluated by two authors (Zhao T, Chen BM) using following words (the  
33  
34  
35 following is an example for Pubmed): (((("hypothyroidism"[MeSH Terms] OR  
36  
37  
38 "hypothyroidism"[All Fields]) OR (subclinical[All Fields] AND ("hypothyroidism"[MeSH  
39  
40  
41 Terms] OR "hypothyroidism"[All Fields]))) AND ("thyroxine"[MeSH Terms] OR  
42  
43  
44 "thyroxine"[All Fields])) AND ("carotid intima-media thickness"[MeSH Terms] OR  
45  
46  
47 ("carotid"[All Fields] AND "intima-media"[All Fields] AND "thickness"[All Fields]) OR  
48  
49  
50 "carotid intima-media thickness"[All Fields] OR ("carotid"[All Fields] AND "intima"[All  
51  
52  
53 Fields] AND "media"[All Fields] AND "thickness"[All Fields]) OR "carotid intima media  
54  
55  
56  
57  
58  
59 6 / 30  
60

1  
2  
3  
4 thickness"[All Fields]). For a thorough review of the literature, we searched more studies by  
5  
6  
7  
8 browsing the references of the identified reports and review articles.  
9

### 10 11 12 **Criteria for study selection** 13

14  
15 Subjects with SCH have standard free thyroxin levels and increased TSH levels. There is still  
16  
17  
18 controversial about the TSH reference interval; several reviews have proposed a TSH upper  
19  
20  
21 cut off between 4.5 and 5.0 mIU/l [9, 10], but some experts suggest that the peak TSH should  
22  
23  
24 be decreased to 2.5-3.0 mIU/l. Because there are no consistent conclusions, no specific TSH  
25  
26  
27 cut off was used to define SCH, but all articles had a cut off point from 3.6 to 5.5 mIU/l. To  
28  
29  
30 be included, a study had to satisfy the following conditions: 1) reported SCH defined based  
31  
32  
33 on a thyroid function test (normal free T4 and increased TSH); 2) defined as a RCT, which  
34  
35  
36 compared C-IMT in SCH patients in a L-T4 treatment and control group, or a self-controlled  
37  
38  
39 trial, which compared C-IMT value of a patient with SCH before and after L-T4 replacement.  
40  
41  
42  
43  
44

### 45 46 **Study selection** 47

48  
49  
50 Two investigators independently screened both abstracts and titles of the studies, and the  
51  
52  
53 studies were excluded when they did not conform to the inclusion criteria or they accorded  
54  
55  
56 with the exclusion criteria. Two investigators independently extracted data from the papers. If  
57  
58  
59

1  
2  
3  
4 there was disagreement, a third reviewer was asked for advice. Discrepancies were solved by  
5  
6  
7  
8 unanimous agreement.  
9

### 10 11 **Data extraction**

12  
13  
14  
15  
16 The following information is contained in the data extraction table: 1) author 2) year of  
17  
18  
19 publication 3) region 4) sample size 5) sample gender 6) mean age of the cohort 7) definition  
20  
21  
22 of SCH 8) duration of SCH 9) SCH detection method 10) mean L-T4 dosage 11) duration of  
23  
24  
25 treatment 12) thyroid function after treatment 13) IMT assessment 14) IMT values (mean  
26  
27  
28 with SD) before and after treatment with the corresponding treatment method.  
29  
30  
31  
32  
33

### 34 **Assessment of study quality**

35  
36  
37  
38 The quality of non-randomized studies was evaluated using the MINORS method [11], which  
39  
40  
41 is based on the following items: a stated aim of the study, inclusion of consecutive patients,  
42  
43  
44 prospective collection of data, endpoint appropriate to the study aim, unbiased evaluation of  
45  
46  
47 endpoints, follow-up period appropriate to the major endpoint, and loss to follow-up not  
48  
49  
50 exceeding 5%.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Methodological quality of the included RCTs was assessed using the Cochrane  
5  
6  
7 Handbook for Systematic Review of Interventions by several domains: generation of random  
8  
9  
10 sequence; allocation concealment; blinding; incomplete outcome data addressed; free of  
11  
12 selective reporting; free of other bias.  
13  
14  
15  
16

### 17 **Statistical analysis**

18  
19  
20 We represented the results as weighted mean differences (WMDs) with 95% confidence  
21  
22 intervals (CIs) for continuous variables. For continuous outcomes, if all reports had uniform  
23  
24 units of measurement (expressed as mm), we showed the WMD and 95% CIs as the results.  
25  
26  
27 We evaluated statistical heterogeneity across the studies by Cochrane's Q test ( $p < 0.1$  was  
28  
29 statistically significant) and the  $I^2$  test ( $I^2 > 50\%$ : high heterogeneity;  $I^2 = 25\%-50\%$ :  
30  
31 moderate heterogeneity;  $I^2 < 25\%$ : low heterogeneity) [12]. In 2011, Kulinskaya et al  
32  
33 suggested a method based on fractional degrees of freedom (df) which substantially improve  
34  
35 the original chi-square distribution with  $s-1$  df, where  $s$  is the number of studies included in the  
36  
37 meta analysis [13]. The pooled effect size was assessed with a random-effect model when  
38  
39 significant statistically heterogeneity was present; in contrast, we also selected a fixed-effect  
40  
41 model.  $p < 0.05$  was considered significant. The weighting of WMD in a fixed-effect model  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 is inverse variance. However, the weighting of WMD in a random-effect model is D-L  
5  
6  
7 method (DerSimonian and Laird method) [14]. We assessed publication bias with Begg's  
8  
9  
10 correlation test and Egger's regression method [15]. Sensitivity analysis was carried out for  
11  
12  
13 all papers in addition to the studies with boundary qualification. Pre-specified subgroup  
14  
15  
16 meta-analyses were performed to assess the between-study heterogeneity on the basis of the  
17  
18  
19 gender of participants (female or genders) and duration of treatment ( $>6$  months or  $\leq 6$   
20  
21  
22 months). Among 9 including studies, 3 out of them are RCTs and the other of them are  
23  
24  
25 self-controlled trials. We performed Statistical analysis of three RCTs. SCH treatment group  
26  
27  
28 of three RCTs also have the information on C-IMT values between pre-treatment and  
29  
30  
31 after-treatment in SCH patients. We combined the SCH treatment group of RCTs with the  
32  
33  
34 other self-controlled trials to performed Statistical analysis for fully revealing the effect of  
35  
36  
37 L-T4 treatment in SCH patients. Statistical analyses were performed with STATA 11 for  
38  
39  
40  
41  
42  
43  
44  
45 Windows.

## 46 47 48 49 **Results**

### 50 51 52 53 **Study selection**

1  
2  
3  
4 Three RCTs [7, 16, 17] (57 patients treated with L-T4 and 60 included in the control group)  
5  
6  
7  
8 were selected for the meta-analysis, with a total of 117 patients. A total of 9 publications [7,  
9  
10  
11 16-23] with 247 SCH patients measured the C-IMT before and after L-T4. We selected these  
12  
13  
14 studies among 107 potentially related articles (Fig. 1).  
15  
16  
17  
18

### 19 **Baseline characteristics and study quality**

20  
21  
22 The baseline characteristics of the included trials are shown in Table 1(A)(B). The duration  
23  
24  
25 of therapy with L-T4 ranged from 2 to 18 months, the patient count varied from 14 to 56  
26  
27  
28 subjects, and the year of the publication was from 2004 to 2016. Six trials included female  
29  
30  
31 and male patients, and the other three only examined female patients. Based on the type of  
32  
33  
34 original research, the methodological evaluation of study quality was different. We used  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
MINORS to assess the quality of the self-controlled trials. In general, the included self-controlled  
trials were of moderate quality (Table1). The results of RCT quality are shown in Fig. 2.

### 59 **Progression of C-IMT in the follow-up and subgroup analysis**

60  
A total of 3 RCTs involving 117 patients were analysed. L-T4 treatment significantly  
decreased C-IMT progression in SCH patients. (WMD, -0.05 mm, 95% CI -0.08, -0.01; p =  
0.025). The heterogeneity was very low ( $I^2=22.2\%$ ) (Fig. 3)

1  
2  
3  
4 The nine self-controlled experiments compared the value of C-IMT before replacement  
5  
6  
7 and after treatment. After L-T4 therapy, the thyroid function of all patients was normalized  
8  
9  
10 from SCH, and then, patient IMT was measured again. Because clinical heterogeneity was  
11  
12 relatively high. We selected random-effect model. L-T4 therapy was associated with a mild  
13  
14 but significant decrease in the development of C-IMT (WMD, -0.04 mm, 95% CI -0.07,  
15  
16  
17  
18 -0.02; p = 0.050). The heterogeneity was moderate. (I<sup>2</sup>=48.3%) (Fig. 4)  
19  
20  
21  
22  
23

24 Subgroup analyses stratified by gender revealed that L-T4 therapy caused a significant  
25  
26 decrease in C-IMT among patients of mixed genders (WMD, -0.03 mm, 95% CI -0.06, -0.01;  
27  
28  
29  
30  
31 p = 0.145). The outcomes showed moderate heterogeneity (I<sup>2</sup>= 39.2%). After L-T4 treatment,  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

TABLE 1(A). Summary of the Characteristics of the Included Studies

Author/ Year	Sample Size	Region	Gender	Mean Age (year)	Definition of SCH	SCH Duration (month)	L-T4 Dosage (initial value)	Treatment Duration (month)	Thyroid function after treatment	CIMT(mm) (Before/After)	Quality Score
Monzani 2004	23	Italy	Mixed genders	37±11	TSH >3.6 mIU/L	at least 6 months	25 -75 ug/d	10.5 <sup>a</sup>	normal	0.76±0.14 0.67±0.13	12
Soo-Kyung 2009	28	Korea	Mixed genders	36.0±6.2	TSH >5.5 mIU/L	newly diagnosed	67µg/d <sup>b</sup>	18 <sup>b</sup>	normal	0.67±0.11 0.60±0.10	9
Monica 2011	14	Brazil	female	43.4±9.8	TSH >4.0 mIU/L	—	44.23±18.13ug/d <sup>d</sup>	12	normal	0.66±0.11 0.66±0.15	10
Levent 2010	38	Turkey	Mixed genders	49.8±10.0	TSH >5.0 mIU/L	at least 2 months	101±27.46µg/d <sup>e</sup>	6 <sup>b</sup>	normal	0.64±0.13 0.63±0.12	11
Nasmi 2016	25	Iran	Mixed genders	35.9±7.6	TSH >4.0 mIU/L	—	50ug/d	2	normal	0.56±0.09 0.57±0.08	11
Ilknur 2014	56	Turkey	Mixed genders	41.3±14.5	TSH >4.2 mIU/L	—	25-50 u/d	—	normal	0.533±0.112 0.507±0.126	12
Dursun 2007	20	Turkey	female	36±11	TSH >4.2 mIU/L	newly diagnosed	25-100ug/d	5 <sup>b</sup>	normal	0.65±0.09 0.55±0.08	12
Adrees 2009	20	Ireland	female	50±9	—	at least 6 months	100 ± 30 ug/d <sup>c</sup>	18	normal	0.82±0.2 0.71±0.2	10
Dilek 2015	23	Turkey	Mixed genders	35.2±10.7	TSH >4.0 mIU/L	at least 6 months	—	6	normal	0.51±0.09 0.46±0.07	11

Abbreviations: TSH, thyroid-stimulating hormone; CIMT, Carotid intima-media thickness; L-T4, levothyroxine.

Mixed genders=including male and female. Age and IMT are expressed as mean± s.d.

<sup>a</sup> median ; <sup>b</sup> mean; <sup>c</sup> mean± s.d; <sup>d</sup> median± interquartile range

TABLE 1(B). Summary of the Characteristics of the Included Studies

Author	TSH assay	Carotid IMT assessment
Monzani	ultrasensitive immunoradiometric assay	both the near and far wall of the right and left common carotid artery and carotid bifurcation (high-resolution ultrasonography)
Soo-Kyung	chemiluminescent immunometric assay	20 mm proximal to the origin of the carotid bulb (high-resolution ultrasonographic system)
Monica	immunochemiluminescence	both the near and far wall of the right and left common artery and the carotid bifurcation. (high-resolution ultrasound imaging)
Levent	Chemiluminescence immunometric assay	approximately 1-cm segment from both the left and right CCA proximal and distal portions (Ultrasonographic images)
Nasmi	–	sonogram B-mode images
Ilknur	electrochemiluminescence immunoassays	Three arterial wall segments of the common carotid artery were measured bilaterally after imaging from a fixed lateral transducer angle and designated (high-resolution B-mode ultrasonography)
Dursun	immunoassay	right and left extracranial carotid arteries: the CCA (1 cm proximal to the dilation of the carotid bulb), the bifurcation (the 1-cm segment proximal to the flow divider), and the internal carotid artery (the 1-cm segment in the internal branch distal to the flow divider). (high-resolution ultrasonography)
Adrees	chemiluminescent immunometric assay	1 cm proximal to the carotid bulb when a satisfactory position was found. (calibrated ultrasound machine)
Dilek	–	ultrasound system

Abbreviations: CCA, common carotid artery.

1  
2  
3  
4 female participants with SCH displayed a significant reduction in C-IMT (WMD, -0.07 mm,  
5  
6  
7 95% CI -0.14, -0.01;  $p = 0.186$ ). The heterogeneity was moderate ( $I^2 = 40.5\%$ ) (Fig.5).  
8  
9

10 Subgroup analyses were performed using the duration of L-T4 replacement. Except for one reports,  
11  
12  
13  
14 all trials had information on the length of the therapy. There was a significant decrease in C-IMT in  
15  
16  
17 the patients with long-term (>6 months) treatment (WMD, -0.05 mm, 95% CI -0.08, -0.02;  $p=0.335$ ).  
18  
19  
20 The outcome showed low heterogeneity ( $I^2 = 12.3\%$ ). A non-significant reduction was found in  
21  
22  
23 C-IMT in the participants with short-term ( $\leq 6$  months) replacement therapy (WMD, -0.04 mm, 95%  
24  
25  
26  
27  
28 CI -0.08, 0.01;  $p=0.015$ ). The heterogeneity was high ( $I^2 = 71.3\%$ ). (Fig. 6).  
29

### 30 **Changes in metabolic parameters**

31  
32  
33  
34 Table 2 indicates the changes in metabolic parameters from pre-replacement to  
35  
36  
37 post-treatment. L-T4 therapy was linked to significant reductions in TC, TG, LDL, SBP,  
38  
39  
40 DBP, and LP(a) and decreased FMD. There were no significant changes in BMI, waist  
41  
42  
43 circumference, HDL, ApoA, ApoB and glucose between the pre-treatment and post-therapy  
44  
45  
46  
47 conditions.  
48

### 49 **Sensitivity and publication bias evaluation**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

We carried out sensitivity analyses by sequentially eliminating one study to probe the change in the total WMD and 95% CI of C-IMT. The results of three RCT indicated no variation

For peer review only



**Table 2**

The difference of the changes in metabolic parameters between pre-treatment and post-treatment.

Parameters	No. of patients	WMD (95% CI)	P-value
Waist circumference (cm)	66	-0.544(-4.041,2.954)	0.761
BMI (kg/m <sup>2</sup> )	152	-0.231(-1.044,0.582)	0.577
Glucose (mmol/L)	48	0.090(-0.109,0.289)	0.375
SBP (mmHg)	109	-9.391(-14.405,-4.377)	<0.001
DBP (mmHg)	109	-5.693(-8.471,-2.916)	<0.001
TC (mg/dl)	166	-9.037(-16.635,-1.439)	0.02
TG (mg/dl)	166	-9.842(-18.763,-0.921)	0.031
HDL (mg/dl)	166	-1.032(-4.059,1.995)	0.504
LDL (mg/dl)	166	-14.303(-19.133,-9.472)	<0.001
FMD (%)	39	3.962(2.636,5.289)	<0.001
ApoA (mg/dl)	37	-10.092(-23.173,2.989)	0.131
ApoB (mg/dl)	37	-7.718(-21.723,6.287)	0.28
LP(a) (mg/l)	34	-9.974(-12.844,-7.103)	<0.001

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; TC, total cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; ApoA, Apolipoprotein A; ApoB, Apolipoprotein B; Lp(a), lipoprotein(a); WMD, weighted mean difference; CI: confidence interval; FMD, flow-mediated dilatation.

in the direction of WMD when each publication was removed. (Fig.s1) . Neither Egger's test (p=0.881) nor Begg's test (p=0.602) of C-IMT in SCH manifested publication biases. ( Fig.s2) ( Fig.s3). We also evaluate the sensitivity and publication bias of the nine self-controlled trial.

The results showed that there was only a slight change in the WMD or 95% CI, and no change in the direction of WMD when any one study was omitted. ( Fig.s4) Egger's test

1  
2  
3  
4 (p=0.458) and Begg's test (p=0.602) of C-IMT in SCH manifested publication biases.  
5  
6

7  
8 ( Fig.s5) ( Fig.s6) .  
9

## 10 **Discussion**

11  
12  
13  
14 This meta-analysis indicated that L-T4 has beneficial effects on the development of C-IMT.  
15

16  
17  
18 Decreased C-IMT was also observed with longer treatment (>6 months). L-T4 therapy of  
19

20  
21 SCH participants also resulted in a significant reduction in TC, TG, LDL, SBP, DBP, LP(a),  
22

23  
24 and FMD.  
25  
26

27  
28 The American Heart Association/American College of Cardiology guidelines designated  
29

30  
31 C-IMT along with coronary artery calcium (CAC) score as a class IIa recommendation for  
32

33  
34 cardiovascular risk assessment in asymptomatic adults at intermediate risk of cardiovascular  
35

36  
37 disease. For a 0.1 mm difference in C-IMT, the prospective risk of myocardial infarction  
38

39  
40 increased from 10% to 15%, and the stroke risk was increased from 13% to 18% [5]. The  
41

42  
43 result showed that C-IMT in SCH patients can be reversed by L-T4 replacement. The  
44

45  
46 mechanism underlying the L-T4-mediated decrease in C-IMT has not been fully elucidated.  
47

48  
49 TSHR, hyperlipidaemia and blood pressure may contribute to this result.  
50  
51

1  
2  
3  
4 In SCH, the increased TSH is the only prominent change, and increased TSH can bind  
5  
6  
7 with the TSH receptor (TSHR) to perform its function. Balzan et al. [24] revealed that  
8  
9  
10 micro-vascular endothelial cells produce TSHR, which may help to elucidate this relationship.  
11  
12  
13 Recently, Tian et al. [25] published a study to identify the potential function of the TSHR and  
14  
15  
16 showed that increased TSH aggravated endothelial dysfunction. However, L-T4 can control  
17  
18  
19 the elevated TSH by reversing above-mentioned changes to reduce the mean C-IMT.  
20  
21  
22  
23

24 Six out of 13 papers in a systemic review reported that L-T4 treatment improved TC and  
25  
26  
27 LDL [26]. A RCT trial with the same conclusion further supported this hypothesis [8].  
28  
29  
30

31 Among four markers of hyperlipidaemia (TC, TG, LDL, HDL), except for HDL we observed  
32  
33  
34 non-significant differences between pre-treatment and post-replacement conditions, which is  
35  
36  
37 supported by previous study with similar findings [27]. Reports by Kannel et al. [28] and  
38  
39  
40 Lewington et al. [29] showed that the TC/HDL ratio is more important in the progress of  
41  
42  
43 coronary heart disease than either TC or HDL alone. Although HDL concentration was not  
44  
45  
46 changed after restoration of euthyroidism by L-T4 replacement in SCH patients in our study,  
47  
48  
49 L-T4 treatment altered the TC/HDL ratio. . Hyperlipidaemia promotes endothelial  
50  
51  
52 dysfunction because it can inhibit the NO synthesis pathway in endothelial cells [30].  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Meanwhile, a recent paper found that SCH can cause endothelial dysfunction because of a  
5  
6  
7 decrease in NO availability, which is partly independent of dyslipidaemia, and L-T4  
8  
9  
10 supplementation can reverse endothelial dysfunction [31]. Thus, we found that SCH not only  
11  
12  
13 results in endothelial dysfunction but is also an independent risk factor of dyslipidaemia; then,  
14  
15  
16 dyslipidaemia further amplifies endothelial dysfunction. L-T4 treatment of SCH patients can  
17  
18  
19 reduce these effects.  
20  
21  
22

23  
24 A meta-analysis showed that blood pressure was an independent risk factor for C-IMT  
25  
26  
27 [32]. Recently, an another meta-analysis demonstrated that SCH is linked to higher SBP and  
28  
29  
30 DBP levels [33]. We know little about the mechanism of SCH-associated hypertension;  
31  
32  
33 nevertheless, hypothyroidism increases vascular resistance, enhances blood pressure, salt  
34  
35  
36 sensitivity and abnormal sodium metabolism, which may promote the development of  
37  
38  
39 hypertension.  
40  
41  
42

43  
44 For the subgroup of short duration ( $\leq 6$  months), an insignificant difference of C-IMT was  
45  
46  
47 observed after treatment. Meanwhile, mean C-IMT in SCH subjects undergoing long-term  
48  
49  
50 treatment significantly increased compared to that in the pre-treatment condition. This  
51  
52  
53  
54  
55 phenomenon was confirmed in our clinical observation. The major reason is that the duration  
56  
57  
58

1  
2  
3  
4 of treatment is too short to improve C-IMT. The rate of progression of IMT in the common  
5  
6  
7  
8 carotid artery was approximately 0.01 mm/year.

9  
10  
11 For stratification by gender, we find a significant difference in female patients between  
12  
13  
14 pre-replacement and post-replacement. Meanwhile, for the mixed genders subgroup, mean  
15  
16  
17 C-IMT was significantly reduced after treatment. Although the prevalence of SCH is a little  
18  
19  
20 difference between women and general population, the effects of levothyroxine (L-T4) on  
21  
22  
23 C-IMT are similar. This suggests that the changes of C-IMT are similar when we control  
24  
25  
26 thyroid function in the normal range regardless of gender.  
27  
28

### 29 30 ***Limitations***

31  
32  
33 The number of including studies was small, and the overall population of these trials was not  
34  
35  
36 large. Meta analysis has moderate heterogeneity. Difficult assessment of the potential  
37  
38  
39 publication bias mainly due to the previous two factors. Additionally, we did not perform  
40  
41  
42 subgroup analysis according to the level of TSH (the cutoff value is 10 mU/ml to distinguish  
43  
44  
45 mild SCH and severe SCH) because the original studies did not perform analyses according  
46  
47  
48 to the level of TSH. Finally, we did not perform subgroup analysis by mean age (>65 or <65  
49  
50  
51 years) because all participants' mean age was below 65 years.  
52  
53  
54

### 55 56 57 **Conclusion**

1  
2  
3  
4 Our study suggests that C-IMT in SCH patients can be reversed by L-T4 replacement.  
5  
6

7  
8 Hyperlipidaemia and hypertension may improve after L-T4 therapy. Long L-T4 replacement  
9  
10 duration (>6 months) is more useful compared to short-term duration for improving C-IMT  
11  
12 in SCH patients. Therefore, L-T4 supplementation can prevent or inhibit the progression of  
13  
14 atherosclerosis, at least in SCH patients. RCTs with more sample size are needed to confirm  
15  
16 these findings.  
17  
18  
19  
20  
21  
22

#### 23 24 contributorship statement 25 26

27  
28 Zhao Tong and Chen Baomin made search strategies, searched papers from  
29  
30 databases, assessed of study quality ,independently extracted data from the papers  
31  
32 and wrote the paper Wang Haoyu as a third reviewer was asked for advice,If there was  
33  
34 disagreement.Zhou Yingying, Wang Xinyi and Zhang Yuanyuan Participated in the  
35  
36 revision of the paper. Shan Zhongyan provided some advices on the discussion section  
37  
38 of this article.  
39  
40  
41  
42  
43  
44  
45  
46

#### 47 48 competing interests statement 49 50

51  
52 The author denies that he has any intention to obtain any financial interests.  
53  
54

#### 55 56 Funding 57 58

1  
2  
3  
4 There are no funders to report for this submission  
5  
6  
7

8 Data Sharing Statement  
9

10 No additional unpublished data are available  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 **References**  
25  
26  
27

- 28 1. Cooper DS. Clinical practice. Subclinical hypothyroidism. *N Engl J Med*. 2001;345(4):260-5. Epub  
29 2001/07/28. doi: 10.1056/nejm200107263450406. PubMed PMID: 11474665.
- 30 2. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism.  
31 A double-blind, placebo-controlled trial. *Annals of internal medicine*. 1984;101(1):18-24. Epub 1984/07/01.  
32 PubMed PMID: 6428290.
- 33 3. Monzani F, Caraccio N, Del Guerra P, Casolaro A, Ferrannini E. Neuromuscular symptoms and dysfunction  
34 in subclinical hypothyroid patients: beneficial effect of L-T4 replacement therapy. *Clin Endocrinol (Oxf)*.  
35 1999;51(2):237-42. Epub 1999/09/01. PubMed PMID: 10468996.
- 36 4. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. *The*  
37 *American journal of cardiology*. 2002;90(10c):18I-21I. Epub 2002/12/03. PubMed PMID: 12459422.
- 38 5. Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH. Carotid intima-media thickness in patients with subclinical  
39 hypothyroidism: a meta-analysis. *Atherosclerosis*. 2013;227(1):18-25. Epub 2012/11/20. doi:  
40 10.1016/j.atherosclerosis.2012.10.070. PubMed PMID: 23159101.
- 41 6. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on  
42 cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized,  
43 crossover trial. *The Journal of clinical endocrinology and metabolism*. 2007;92(5):1715-23. Epub 2007/02/15.  
44 doi: 10.1210/jc.2006-1869. PubMed PMID: 17299073.
- 45 7. Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Viridis A, et al. Effect of levothyroxine  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-  
4 controlled study. *The Journal of clinical endocrinology and metabolism*. 2004;89(5):2099-106. Epub  
5 2004/05/06. doi: 10.1210/jc.2003-031669. PubMed PMID: 15126526.

6  
7  
8 8. Andersen MN, Olsen AM, Madsen JC, Faber J, Torp-Pedersen C, Gislason GH, et al. Levothyroxine  
9 Substitution in Patients with Subclinical Hypothyroidism and the Risk of Myocardial Infarction and Mortality.  
10 *PLoS One*. 2015;10(6):e0129793. Epub 2015/06/13. doi: 10.1371/journal.pone.0129793. PubMed PMID:  
11 26069971; PubMed Central PMCID: PMC4466400.

12  
13 9. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the  
14 evidence for the U.S. Preventive Services Task Force. *Annals of internal medicine*. 2004;140(2):128-41. Epub  
15 2004/01/22. PubMed PMID: 14734337.

16  
17 10. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific  
18 review and guidelines for diagnosis and management. *Jama*. 2004;291(2):228-38. Epub 2004/01/15. doi:  
19 10.1001/jama.291.2.228. PubMed PMID: 14722150.

20  
21 11. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized  
22 studies (minors): development and validation of a new instrument. *ANZ journal of surgery*. 2003;73(9):712-6.  
23 Epub 2003/09/06. PubMed PMID: 12956787.

24  
25 12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ (Clinical*  
26 *research ed)*. 2003;327(7414):557-60. Epub 2003/09/06. doi: 10.1136/bmj.327.7414.557. PubMed PMID:  
27 12958120; PubMed Central PMCID: PMC192859.

28  
29 13. Kulinskaya E, Dollinger MB, Bjorkestol K. Testing for homogeneity in meta-analysis I. The one-parameter  
30 case: standardized mean difference. *Biometrics*. 2011;67(1):203-12. doi: 10.1111/j.1541-0420.2010.01442.x.  
31 PubMed PMID: 20528863.

32  
33 14. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. *Contemporary clinical trials*. 2015;45(Pt  
34 A):139-45. Epub 2015/09/08. doi: 10.1016/j.cct.2015.09.002. PubMed PMID: 26343745; PubMed Central  
35 PMCID: PMC4639420.

36  
37 15. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with  
38 publication and other biases in meta-analysis. *BMJ (Clinical research ed)*. 2001;323(7304):101-5. Epub  
39 2001/07/14. PubMed PMID: 11451790; PubMed Central PMCID: PMC1120714.

40  
41 16. Cabral MD, Teixeira P, Soares D, Leite S, Salles E, Waisman M. Effects of thyroxine replacement on  
42 endothelial function and carotid artery intima-media thickness in female patients with mild subclinical  
43 hypothyroidism. *Clinics (Sao Paulo)*. 2011;66(8):1321-8. doi: 10.1590/S1807-59322011000800003. PubMed  
44 PMID: 21915478; PubMed Central PMCID: PMC3161206.

45  
46 17. Duman D, Demirtunc R, Sahin S, Esertas K. The effects of simvastatin and levothyroxine on intima-media  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
25 / 30



1  
2  
3 thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective,  
4 randomized-controlled study. *J Cardiovasc Med (Hagerstown)*. 2007;8(12):1007-11. doi:  
5 10.2459/JCM.0b013e3282f03bc1. PubMed PMID: 18163011.  
6  
7

8 18. Unsal IO, Topaloglu O, Cakir E, Bozkurt NC, Karbek B, Gungunes A, et al. Effect of L-thyroxin therapy on  
9 thyroid volume and carotid artery intima-media thickness in the patients with subclinical hypothyroidism. *J*  
10 *Med Disord*. 2014;2(1):1. doi: 10.7243/2053-3659-2-1.  
11  
12

13 19. Kebapcilar L, Comlekci A, Tuncel P, Solak A, Secil M, Gencil O, et al. Effect of levothyroxine replacement  
14 therapy on paraoxonase-1 and carotid intima-media thickness in subclinical hypothyroidism. *Med Sci Monit*.  
15 2010;16(1):CR41-7. PubMed PMID: 20037493.  
16  
17

18 20. Adrees M, Gibney J, El-Saeity N, Boran G. Effects of 18 months of L-T4 replacement in women with  
19 subclinical hypothyroidism. *Clinical endocrinology*. 2009;71(2):298-303. doi:  
20 10.1111/j.1365-2265.2008.03509.x.  
21  
22

23 21. Yazıcı D, Özben B, Toprak A, Yavuz D, Aydın H, Tarçın Ö, et al. Effects of restoration of the euthyroid state  
24 on epicardial adipose tissue and carotid intima media thickness in subclinical hypothyroid patients. *Endocrine*.  
25 2014;48(3):909-15. doi: 10.1007/s12020-014-0372-1.  
26  
27

28 22. Niknam N, Khalili N, Khosravi E, Nourbakhsh M. Endothelial dysfunction in patients with subclinical  
29 hypothyroidism and the effects of treatment with levothyroxine. *Advanced biomedical research*. 2016;5:38.  
30 Epub 2016/04/22. doi: 10.4103/2277-9175.178783. PubMed PMID: 27099851; PubMed Central PMCID:  
31 PMCPmc4815523.  
32  
33

34 23. Kim SK, Kim SH, Park KS, Park SW, Cho YW. Regression of the increased common carotid artery-intima  
35 media thickness in subclinical hypothyroidism after thyroid hormone replacement. *Endocr J*. 2009;56(6):753-8.  
36 Epub 2009/06/10. PubMed PMID: 19506325.  
37  
38

39 24. Balzan S, Del Carratore R, Nicolini G, Beffy P, Lubrano V, Forini F, et al. Proangiogenic effect of TSH in  
40 human microvascular endothelial cells through its membrane receptor. *The Journal of clinical endocrinology*  
41 *and metabolism*. 2012;97(5):1763-70. Epub 2012/03/16. doi: 10.1210/jc.2011-2146. PubMed PMID: 22419707.  
42  
43

44 25. Tian L, Zhang L, Liu J, Guo T, Gao C, Ni J. Effects of TSH on the function of human umbilical vein endothelial  
45 cells. *Journal of molecular endocrinology*. 2014;52(2):215-22. Epub 2014/01/22. doi: 10.1530/jme-13-0119.  
46  
47  
48 PubMed PMID: 24444496.  
49

50 26. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on  
51 serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. *The Journal of*  
52 *clinical endocrinology and metabolism*. 2000;85(9):2993-3001. Epub 2000/09/22. doi: 10.1210/jcem.85.9.6841.  
53  
54  
55 PubMed PMID: 10999775.  
56

57 27. Asranna A, Taneja RS, Kulshreshta B. Dyslipidemia in subclinical hypothyroidism and the effect of  
58  
59  
60

1  
2  
3 thyroxine on lipid profile. *Indian J Endocrinol Metab.* 2012;16(Suppl 2):S347-9. Epub 2013/04/09. doi:  
4 10.4103/2230-8210.104086. PubMed PMID: 23565423; PubMed Central PMCID: PMC3603071.

5  
6 28. Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ. Usefulness of the triglyceride-high-density  
7 lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and  
8 cardiometabolic risk (from the Framingham Offspring Cohort). *The American journal of cardiology.*  
9 2008;101(4):497-501. Epub 2008/03/04. doi: 10.1016/j.amjcard.2007.09.109. PubMed PMID: 18312765;  
10 PubMed Central PMCID: PMC3753679.

11  
12 29. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular  
13 mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with  
14 55,000 vascular deaths. *Lancet.* 2007;370(9602):1829-39. Epub 2007/12/07. doi:  
15 10.1016/s0140-6736(07)61778-4. PubMed PMID: 18061058.

16  
17 30. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction:  
18 dysregulation of dimethylarginine dimethylaminohydrolase. *Circulation.* 1999;99(24):3092-5. Epub 1999/06/22.  
19 PubMed PMID: 10377069.

20  
21 31. Taddei S, Caraccio N, Viridis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired endothelium-dependent  
22 vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. *The Journal of clinical*  
23 *endocrinology and metabolism.* 2003;88(8):3731-7. Epub 2003/08/14. doi: 10.1210/jc.2003-030039. PubMed  
24 PMID: 12915662.

25  
26 32. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, et al. Carotid intima-media thickness and  
27 antihypertensive treatment: a meta-analysis of randomized controlled trials. *Stroke; a journal of cerebral*  
28 *circulation.* 2006;37(7):1933-40. Epub 2006/06/10. doi: 10.1161/01.str.0000227223.90239.13. PubMed PMID:  
29 16763185.

30  
31 33. Cai Y, Ren Y, Shi J. Blood pressure levels in patients with subclinical thyroid dysfunction: a meta-analysis of  
32 cross-sectional data. *Hypertension research : official journal of the Japanese Society of Hypertension.*  
33 2011;34(10):1098-105. Epub 2011/07/29. doi: 10.1038/hr.2011.91. PubMed PMID: 21796125.

34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48 Fig.1. Process of study selection.

49  
50  
51  
52 Abbreviations: IMT: intima-media thickness; SCH: subclinical hypothyroidism

53  
54  
55  
56 Fig.2. Quality assessment of the included studies.

1  
2  
3  
4 Fig.3. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals for improvement  
5  
6  
7  
8 in carotid intima-media thickness comparing L-T4 treatment to the control in a fixed effects model.  
9

10  
11 Legend for x-axis: Negative values equals improvement in IMT.  
12  
13

14  
15  
16  
17  
18 Fig.4. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals compared the  
19  
20  
21 value of C-IMT before replacement and after treatment in a random-effect model.  
22  
23

24  
25 Legend for x-axis: Negative values equals improvement in IMT.  
26  
27

28  
29  
30  
31 Fig.5.Subgroup analyses of carotid intima-media thickness changes based on gender in a random effects model.  
32  
33

34  
35 Legend for x-axis: Negative values equals improvement in IMT.  
36  
37

38  
39  
40  
41 Fig.6.Subgroup analyses of carotid intima-media thickness changes based on duration of L-T4 replacement in a  
42  
43  
44  
45 random effects model.  
46

47  
48 Legend for x-axis: Negative values equals improvement in IMT.  
49  
50

51  
52 Long study duration= duration of L-T4 replacement >6 months  
53

54  
55 Short study duration= duration of L-T4 replacement ≤6 months  
56  
57

1  
2  
3  
4  
5  
6  
7  
8 Fig.S1 Begg's funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in  
9  
10  
11 RCT studies.

12  
13  
14  
15  
16  
17  
18 Fig.S2 Begg's funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in  
19  
20  
21 self-controlled studies.

22  
23  
24  
25  
26  
27  
28 Fig.S3 Funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in RCT  
29  
30  
31 studies .


32  
33  
34  
35  
36  
37  
38 Fig.S4 Funnel plot with pseudo 95% confidence limits of publication bias test for L-T4 on C-IMT in  
39  
40  
41 self-controlled studies.

42  
43  
44  
45  
46  
47  
48 Fig.S5 Sensitivity analysis of the RCT studies included in the meta-analysis. The figure shows the WMD  
49  
50  
51  
52 obtained by combined analysis of the remaining studies after the successive exclusion of each study individually.

53  
54  
55 The excluded study is listed on the left, and the corresponding horizontal lines indicate the WMD and CI

1  
2  
3  
4 obtained by re-calculation after its exclusion. The CI for the overall meta-analysis of the studies is indicated by  
5  
6  
7 two vertical lines.  
8  
9

10  
11  
12  
13  
14 Fig.S6 Sensitivity analysis of the self-controlled studies included in the meta-analysis. The figure shows the  
15  
16  
17 WMD obtained by combined analysis of the remaining studies after the successive exclusion of each study  
18  
19  
20 individually. The excluded study is listed on the left, and the corresponding horizontal lines indicate the WMD  
21  
22  
23 and CI obtained by re-calculation after its exclusion. The CI for the overall meta-analysis of the studies is  
24  
25  
26  
27 indicated by two vertical lines.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Fig.1. Process of study selection. !! + Abbreviations: IMT: intima-media thickness; SCH: subclinical hypothyroidism.

180x243mm (600 x 600 DPI)




Fig.2. Quality assessment of the included studies.

58x19mm (600 x 600 DPI)

peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.3. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals for improvement in carotid intima-media thickness comparing L-T4 treatment to the control in a fixed effects model.

Legend for x-axis: Negative values equals improvement in IMT.

115x74mm (600 x 600 DPI)

ew only






Fig.4. Forest plots showing WMD (weighted mean differences) with 95% confidence intervals compared the value of C-IMT before replacement and after treatment in a random-effect model. Legend for x-axis: Negative values equals improvement in IMT.

128x92mm (600 x 600 DPI)




Fig.5.Subgroup analyses of carotid intima-media thickness changes based on gender in a random effects model.

Legend for x-axis: Negative values equals improvement in IMT.

138x106mm (600 x 600 DPI)




Fig.6.Subgroup analyses of carotid intima-media thickness changes based on duration of L-T4 replacement in a random effects model.

Legend for x-axis: Negative values equals improvement in IMT.  
 Long study duration= duration of L-T4 replacement >6 months  
 Short study duration= duration of L-T4 replacement ≤6 months

140x109mm (600 x 600 DPI)

only

Meta-analysis estimates, given named study is omitted

| Lower CI Limit

○ Estimate

| Upper CI Limit

F. MONZANI

Monica Dias Cabral

Dursun Duman

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>


0.04

0.08


0.05

0.01


0.02



# Begg's funnel plot with pseudo 95% confidence limits



## Funnel plot with pseudo 95% confidence limits




Meta-analysis estimates, given named study is omitted


| Lower CI Limit

○ Estimate

| Upper CI Limit




Begg's funnel plot with pseudo 95% confidence limits



For peer review only - <http://bmjopen.bmj.com/site/abou/guidelines.xhtml>





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

-0.15 peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml> 0 0.05 0.1

WMD



# PRISMA 2009 Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5-6
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8-9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ for each meta-analysis).	9



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8-9
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	11
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	17
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	15
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	18
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	18
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	18
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19-20
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	3
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	25
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	25

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>